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_I_ Aim of the study 
Over the last few decades, the availability of new techniques, such as immuno-
histochemical techniques, DNA-analysis, recombinant DNA-analysis and imaging 
techniques, has been one of the incentives for the development of new diagnostic 
tests. Computer tomography and magnetic resonance imaging are examples of 
techniques that are useful for the diagnosis of many different diseases. A recent 
example of a test for one particular disease is the immunohistochemical test based 
on anti-keratin antibodies for the diagnosis of ovarian carcinoma.' 
The aim of new diagnostic tests is to establish diagnoses faster and more 
efficiently. To determine whether this aim is achieved, assessment studies are 
necessary before the new test is implemented in the diagnostic process. 
In the current practice of this diagnostic process, the probability of the presence 
of disease is estimated for a patient presenting with certain complaints. Often, this 
probability is not 100%, but lower, e.g. 60%. A diagnostic test is then carried out 
to gain more certainty about the presence of disease. A positive test result provides 
greater certainty about the presence of a particular disease. The probability of 
disease presence is estimated with Bayes' theorem, in which the sensitivity and 
specificity, or likelihood ratio, as measures for the amount of information of a test 
are ingredients of crucial importance.*"1 Sensitivity and specificity are usually 
determined in assessment studies, but unfortunately, they are often biased.3 These 
biases are the result of assessment in inadequate study populations. Furthermore, 
frequently too little information is provided in assessment studies. The use of 
biased estimates of sensitivity and specificity will lead to incorrect estimates of the 
probability of the presence of disease. Moreover, inflated or deflated estimates of 
sensitivity and specificity will result in inexpedient use of diagnostic tests. 
The assessment of carcinoembryonic antigen (CEA) in the diagnosis of 
colorectal carcinoma is the most striking example of current assessment practice 
and its consequences. The first publication on the potential usefulness of CEA 
appeared in 19656 and soon CEA assessment was routinely requested in the 
diagnostic work-up of patients suspected of having colorectal carcinoma. Some ten 
years later, it became commonly accepted among investigators that CEA could not 
be used in making the diagnosis.7 However, in 1982 50% of the physicians of 
Duke University Medical Centre, Durham, NC, still believed in its usefulness for 
diagnostic purposes.' 
A more extensive assessment procedure is necessary, with assessment in the 
adequate population and adequate statistical analyses. With such an assessment 
procedure the preliminary introduction of tests with bad diagnostic performance 
into clinical practice can be prevented. The aim of the present investigation is to 
develop an adequate assessment procedure for new diagnostic tests, resulting in the 
guidelines such as they will be made explicit in the present thesis. Furthermore, in 
this thesis, applications of the guidelines in clinical practice are presented. The 
procedure as a whole is based on the principle that an extensive assessment is not 
necessary for tests that can hardly discriminate between diseased and healthy 
individuals, which, unfortunately, is not uncommon. Since the diagnostic process 
has always been interwoven with the process of diagnostic test assessment, first the 
theory of diagnosis will be elaborated versus the theory of diagnostic test 
assessment. 
Guidelines are presented with recommendations for the design and statistical 
analyses of assessment studies. With respect to the patient population, it is 
explained that patients with a clinical indication for the test form the only adequate 
population. Patients have an indication for a test because they are suspected of 
having the disease which the test is supposed to diagnose. With respect to the 
statistical analyses, a plea for Receiver Operating Characteristic (ROC) analysis 
and also for logistic regression analysis is made. ROC curves utilize the full 
information content of a diagnostic test, in case the test is measured on an ordinal 
or continuous scale. With logistic regression analysis, the contribution of the new 
test to the existing diagnostic arsenal can easily be estimated. 
The use of the guidelines developed is illustrated by applications in clinical 
practice. To illustrate the problems encountered in the development of a new 
diagnostic test, the development of items of a motor performance test for the 
functional discrimination between children with and without myopathy is 
discussed. The initial assessment of a test in an indicated population is illustrated 
with reference to an old test (CEA) and three new ones (CA 19-9, CA 50, CA 
195) for colorectal carcinoma, respectively. It was not our purpose to disguise the 
fact that in practice problems will be encountered when an indicated population 
has to be selected. This thesis particularly describes some of the problems that 
arise when an assessment study is done with data from existing files and the 
consequences of such problems. Finally, the assessment of the contribution of a 
new test to the existing arsenal is illustrated by the assessment of ultrasonography 
in the diagnosis of hypertrophic pyloric stenosis. 
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Part One 
Theory of diagnosis, diagnostic test assessment 
and guidelines 

2 Theory of diagnosis and assessment of new diagnostic tests 
Making diagnoses is one of the most elementary processes in medical practice. Its 
purpose is to estimate the probability that a particular disease is the cause of the 
complaints, symptoms and signs the patient is presenting. Making diagnoses, 
however, is no goal in itself. The estimation of the probability of disease presence 
is meaningful for guiding therapeutical decisions and indicating prognoses. 
Diagnoses are based on information provided by the patient such as age and 
gender, the presence of signs and symptoms and information from the physical 
examination. In many instances it is not immediately known with certainty from 
this information whether a particular disease is present or not, so a diagnostic test 
is applied. Which test will be chosen depends on the diagnostic performance of the 
available appropriate tests. Mistakes may have serious consequences for individual 
patients. Therefore, it is important to use tests with good diagnostic performance. 
Such performance is determined in assessment studies. This chapter will provide 
insight into the use of information from assessment studies in the process of 
making diagnoses. 
Diagnostic strategies 
Information provided by the patient, e.g. complaints, signs or symptoms, and by 
diagnostic tests usually does not reveal a patient's true disease status. In most 
instances, the information is representative of more than one disease. The 
uncertainty about the true disease status can be expressed by a figure, the 
probability of disease. When making a diagnosis, it is tried to estimate the 
probability of disease being present. 
Sackett et al. distinguish four strategies to make a diagnosis.1 The first one is 
pattern recognition. In this strategy a patient's presentation conforms to a 
previously learned picture (or pattern) of disease which is recognized immediately, 
such as Down's syndrome. The second one is the arborization strategy, in which 
an algorithm is used. Each diagnostic question follows the preceding one logically, 
until the final diagnosis is reached. Algorithms have, for example, been developed 
for chest pain.2 The third strategy is the exhaustion strategy: the undeliberate 
search for all medical facts about the patient from which the diagnosis has to be 
distilled. Medical students are often taught to make diagnoses through the 
exhaustive strategy. The fourth and most important strategy is iterative hypothesis 
testing. When it is clear which complaints the patient suffers from, a few potential 
diagnoses can be formulated in a so-called differential diagnosis. A probability oi 
disease being present is assigned to each diagnosis, often implicitly. By carefully 
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asking specific questions, for example about the patient's medical history and 
symptoms and by doing diagnostic tests, the probability of each of these diagnoses 
being correct is "adjusted" The adjustment with new diagnostic information 
continues until for one diagnosis the probability is high enough to initiate 
treatment How high "high enough" actually is, depends on the costs and benefits 
of the applied treatment Costs comprise, for example, monetary value, patient's 
discomfort, adverse effects or risks, and consequences of false positive errors 3 4 
Benefits of treatment comprise the curative effect of treatment 
Setting diagnoses with Bayes' theorem 
For a certain patient with specific complaints, the probability that a particular 
disease is present is estimated to be P(D + ), say, 60% As this probability is not 
high enough to initiate treatment, a diagnostic test is applied, of which the result is 
positive Now the probability of disease is P ( D + | T + ) , for example 80% This 
latter probability is the posterior probability of disease, ι e the probability of 
disease presence conditional on a test result The probability of disease as 
estimated before this test result was known is the prior probability of disease 
For the calculation of the posterior probability of disease, the intrinsic value of 
the diagnostic test is used, ι e its sensitivity and specificity These intrinsic values 
are substituted in Bayes' theorem 
prior odds of disease * Ukehhood Ratio (LR) - postenor odds of disease 
From the posterior odds the posterior probability can easily be calculated, as 
probability = odds/(l + odds) Written out in full, Bayes' theorem is 
ΡΦΊ , Ρ(Τ'\ρη
 =
 РфІГ) 
P(D ) P(T'\D-) P(D \Γ) 
or 
prior probability of disease sensitivity 
1 minus prior probability of disease 1 minus specificity 
If the posterior probability is still not high enough to initiate treatment, a new 
diagnostic test is applied and Bayes' theorem is filled in again, with the initial 
posterior probability now serving as prior probability for the new test. The entire 
diagnostic process can be summarized as: 
Posterior odds - Prior odds * LA, * LRj * ... * Lr
m 
Problems in the ase of Bayes' theorem 
Although the Bayesian way of diagnosing via iterative hypothesis testing is correct, 
it has been criticized. Criticism focuses especially on the fact that sensitivity and 
specificity have rather arbitrary values. Many diagnostic tests have results that are 
not simply positive or negative, but can be measured on a continuous scale. To be 
able to calculate test characteristics, a certain level is chosen above which a test 
result is positive and below which it is negative. Sensitivity and specificity are 
dependent on the cut-off level that is chosen for test-positivity.5·6 
Furthermore, when the information of several diagnostic tests is used for 
setting the diagnosis. Bayes' theorem is applied several times in a row; each 
posterior probability serves as prior probability for the next test. However, the 
iterative application of Bayes' theorem assumes statistical independence of the 
diagnostic features, which is seldom the case. To a certain extent tests usually 
provide the same information. Sensitivity and specificity based on the joint 
characteristics of tests might be meaningful, but are rarely available.7 
Third, sensitivity and specificity depend on the population they are derived 
from, which is often a referred population. Usually, patients are referred or 
further diagnostic work-up is done because certain complaints, symptoms or 
positive results of other tests were present. Patients without complaints or with 
negative tests are less likely to be referred. The resulting test characteristics cannot 
simply be applied to all patients before referral.5'·8'14 In general, if patients with a 
positive test result have probability r+ of referral to hospital and patients with a 
negative result probability r_, then sensitivity and specificity will vary according to 
the population in which they are determined: the original, or the "referral" or 
hospital population as is elaborated in Figure I.14·" This, by the way, is only the 
case if Tt Φ r_. So test characteristics are susceptible to selection bias. 
Finally, in determining test results and the true disease status of patients by the 
use of a golden standard, some test results will be uninterpretable and some 
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Sens = proportion of patients with a positive test result 
Spec = proportion of non-patients with a negative test result 
r+ = referral rate for patients with a positive test result 
r. = referral rate for patients with a negative test result 
* denotes situation after referral 
Sens* > Sens, provided that r+ > r-
Spec* < Spec, provided that r+ > r-
Figure 1 Sensitivity and specificity of a diagnostic test Τ in the original (Sens, 
Spec) and 'referred' populations (Sens', Spec') 
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patients will be lost to follow-up, so data on test results and disease statuses will be 
missing. The uninterpretability or unavailability of data will often be associated 
with disease and estimates of sensitivity and specificity will be biased if these 
results are omitted from the analyses.516·'7 
Logistic regression analysis in diagnosis 
Essentially, making a diagnosis in the sense of determining the probability of 
having D+ is the same as determining the probability of having I, conditional on 
all factors that influence this probability: P(D+ |F, ... FJ. Factors F, to FB repre-
sent symptoms, complaints, diagnostic test results, etc. Besides the iterative 
application of Bayes' theorem, another method to estimate this conditional 
probability is available, viz. the logistic regression method. In the logistic 
regression method it is attempted to estimate the conditional probability PflD+jf,, 
f¡. ···. fj • P(D+ |x) directly from the data via the model: 
P(J) = ΛΟ*ΙΛ = —.= (5) 
1 • e1 4* ' W 1 • «<· * '» 
where the row vector f = [f,, f2, ..., fj and ß' = [ß„ ß2, ..., β,). The graph of 
the logistic function is shown in Figure 2. In the logistic model the ß,s are 
estimated in such a manner that P(D+ ¡ f) varies between one and zero. Because of 
this property and because of the sigmoidal shape of the function, it is often used to 
model the probability of disease as a function of various independent variables 
known or suspected to be related to disease development." For making diagnoses 
with logistic regression functions, ßs have to be known from literature or 
estimated in assessment studies instead of sensitivities and specificities. 
In the previous section, four problems involved in the use of Bayes' theorem 
for making diagnoses were identified. The problem of the cut-off dependency of 
the intrinsic values of a diagnostic test does not play a role in logistic regression 
analysis, as the absolute test result can be substituted in the function. The difficulty 
in estimating the joint intrinsic values of dependent tests is easily solved by fitting 
both tests in the regression function. In contrast to sensitivity and specificity, fis 
are not susceptible to selection bias, as long as the selection factors are included in 
the model. Only the problem of uninterpretable test results and absence of true 
disease status remains unchanged in the use of logistic regression analysis. 
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Considering all this, logistic regression analysis is far more attractive for making 
diagnoses than Bayes' theorem. 
ЛУ)4 
Figure 2 Graph of the logistic function 
Setting diagnoses versus assessment 
Whatever method is used for estimating the probability of disease presence, 
information of a diagnostic test is always necessary. For Bayes' theorem the 
sensitivity and specificity have to be known, whereas for logistic regression 
analysis beta-coefficients must be available. For this information to be useful for 
making diagnoses, the information should be invariant, so the information used as 
input in logistic regression analysis seems most adequate. When estimates of beta-
coefficients of diagnostic tests are not available from the literature, they have to be 
estimated in assessment studies. These studies should be carried out in the relevant 
population, i.e. the population consisting of patients with a clinical indication for 
the application of the test, because they are suspected of having the particular 
disease the test is meant to diagnose, as will be elaborated in the next chapter. 
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Guidelines for the assessment of new diagnostic 
tests 
Abstract 
Owing to the growing number of new diagnostic tests flooding the market a need 
has grown for proper evaluation of tests before their implementation in clinical 
practice. Three topics are of pivotal importance: the selection of the proper study 
population, the determination of the diagnostic power with its related statistical 
analysis, and the relationship of the new test with current diagnostic tools. The 
population of real interest with a view to applying a diagnostic test consists of 
patients suspected of having the disease. Therefore, only those patients have to be 
involved in the assessment study. Summary measures of the diagnostic power 
other than sensitivity and specificity will be advocated because these conventional 
measures are dependent on cut-off points and susceptible to selection bias. Finally, 
it is important to establish the relationship between the new test and existing 
diagnostic tools to see whether the new test really contributes to the diagnostic 
process. In order to avoid waste of efforts and money, we suggest a prudent 
assessment approach in phases. Whereas the initial challenge consists in the 
selection of the adequate patient population, later on all determinants of the disease 
(signs, symptoms, comorbidity and other diagnostic tests) and factors influencing 
the decision whether or not to use a test (patient burden and cost) are dealt with. 
The analytical concepts, comprising the presentation of the full information content 
of the test and the way to deal with all determinants simultaneously, will be 
illustrated with data on ultrasound assessment studies for hypertrophic pyloric 
stenosis. 
Over the past years many new diagnostic tests have been developed and introduced 
into clinical practice. As a consequence of the increase in the number of diagnostic 
tests becoming available, a need has grown for proper evaluation of tests before 
their implementation. A number of proposals have been made for guidelines along 
which new diagnostic tests should be evaluated.1"6 In our view, three topics are of 
central importance in diagnostic test assessment: 1) the selection of the proper 
study population, 2) the definition of diagnostic power with its related statistical 
analysis, and 3) the relationship of the new test with current diagnostic tools. 
These will be worked out here with particular emphasis on the first topic. 
For assessment of a test, usually the test results of healthy people are compared 
with those of patients already known to be suffering from the disease: the easily 
accessible population. In clinical practice, however, the test is used to distinguish 
between the presence and absence of disease among patients all having certain 
symptoms and manifesting particular signs. In this so-called "indicated" population 
it is more difficult to discriminate between suspected patients with the illness and 
those without, because it is highly probable that the test outcome is associated with 
the complaints, signs or symptoms of the study patients. It is the assessment in an 
indicated population that we are interested in.7 To carry out an assessment in ал 
easily accessible population can only be useful from a pragmatic and logistic point 
of view. Does the test perform badly here, which is not uncommon, it will 
certainly perform worse in the indicated population. Although most authors of 
guidelines recognize the need for assessment in the indicated population, in general 
great emphasis is laid on evaluation in easily accessible populations.*·* 
The second point to be stressed in assessment studies is the definition of 
diagnostic power and the associated statistical analytical methods. Commonly, 
diagnostic power is ascribed to a qualitative diagnostic test if it yields a higher test 
result more frequently in the diseased group than in the non-diseased group. The 
results of quantitative tests, on the other hand, are often dichotomized, usually at 
the 95th centile of the test result distribution in healthy persons,10 so as to make 
the test a qualitative one. Dichotomization deprives a test of its full informative 
content, and may thus lead to substantial loss of information. Yet, it is still often 
recommended to present assessment results in a dichotomous format,1"*'* which 
weakens their usefulness owing ti their cut-off point dependency and susceptibility 
to selection bias (Chapter 6). Selection bias can occur as a result of differential 
verification for patients with positive and negative test results9 or as a result of 
studying only a part of the entire disease spectrum,'° as is done in an easily 
accessible population. 
Finally, it is also important to establish the relationship between the new test 
22 Chapter! 
and existing diagnostic tools to see whether the new test really contributes to the 
diagnostic power. It might be possible to leave out one or more of the older tests 
or, indeed, the new test. The need for assessing the contribution of the new test to 
the existing diagnostic arsenal, including other diagnostic tests, is hardly 
recognized in other guidelines. 
Diagnostic process and assessment of new tests 
A patient will visit his doctor because he suffers from certain complaints and/or 
symptoms. The doctor will -implicitly- make a list of diseases that are typically 
attended by the complaints, signs and symptoms which the patient experiences. A 
probability of disease presence is assigned to each disease on the list. If one 
probability is high enough, treatment will be initiated. If no probability is high 
enough, a diagnostic test will be done. Whether a probability is sufficiently high 
for treatment depends on the benefit of the treatment, the risk or cost of the 
diagnostic test and the cost of treatment for patients who do not actually have the 
disease, but, for example, are treated because of a false positive test result.10 The 
assigned probabilities of disease presence are adjusted for each disease on the basis 
of a test result. Usually, sensitivity and specificity (see Table 1) of the applied test 
are used to update the probability of disease presence according to Bayes' 
theorem. Hence, in diagnosis a strong need exists to know the information a test 
result bears, e.g. by giving the sensitivity and specificity. 
In assessment studies of new tests, predominantly estimates of the test 
"characteristics" are presented. Unfortunately, for assessment, sensitivity and 
specificity do not always provide the relevant information, because of their 
dependency on cut-off points and their susceptibility to selection bias. This will be 
addressed later on. 
Assessment in phases 
The present paper is concerned with the formulation of new guidelines for 
diagnostic test assessment, in which the main challenge consists in the selection of 
the adequate study population. It will be confined to anatomically and causally 
defined diseases, so as to prevent problems with the golden standard or definitive 
diagnosis. Anatomically defined diseases are defined by an anatomical lesion, such 
as a malignant tumor. As the name indicates, causally defined diseases are 
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Table 1 Information of a dicholomous diagnostic test as presented in a fourfold table 
Test resuit 
Positive 
Negative 
Disease 
Present Absent 
320 
80 
60 
540 
400 600 
380 
620 
1000 
Sensitivity: proportion of diseased with positive test result = 320/400 = 80% 
Specificity: proportion of non-diseased with negative test result = 540/600 = 
90% 
Likelihood ratio positive: proportion of diseased and non-diseased with positive 
test result = ((3201400)1(601600)) = 8 
Prevalence of disease in test-positive group = 320/380 = 84% 
Prevalence of disease in test-negative group = 80/620 =13% 
characterized by an unequivocal factor as the cause of the disease, such as the 
tubercle bacillus in the case of tuberculosis." Syndromes, defined by a 
concurrently existing set of characteristics, and complaint diagnoses, defined by a 
complaint rather than a cause, are not under consideration in this paper. 
Diagnostic test assessment is a major enterprise entailing great efforts. In order 
to avoid waste of efforts and money, it must be established as soon as possible 
whether a diagnostic test is potentially worthwhile or not. We therefore advocate a 
prudent approach of diagnostic test evaluation in several phases, each of which has 
to be passed with success before the next assessment phase can be started. 
Whereas initially the challenge consists in the selection of adequate patient 
population, later on other determinants of the disease are dealt with as well, such 
as the clinical and non-clinical profile, comorbidity and the results of other 
diagnostic tests, and other factors influencing the decision whether or not to use a 
test, such as costs and patient burden. Obviously, not all new tests will need such 
an extensive assessment. In some instances it is soon established that test results 
among the diseased and non-diseased are virtually identical. In that case, the test is 
not adequate yet. 
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Test development 
Strictly speaking, the development of a diagnostic test does not fall within the 
scope of test evaluation. Nevertheless, it is important that some facts of the new 
test are known before actual assessment starts. Among these are (1) minimum 
detection level and cross-reactivity in the case of a biochemical test; (2) 
measurement errors; (3) repeatability (which must be high, otherwise the test will 
never meet diagnostic assessment standards); (4) required personnel and 
equipment; (5) compliance of participants; (6) dose and pharmacokinetics in the 
case of a pharmaceutical test, and so forth. We only point to the importance of 
these facts but, as explained above, will not further elaborate on test development 
aspects. 
Test application in an easily accessible population 
This phase of diagnostic test assessment, which is not obligatory, may be 
employed for pragmatic and logistic reasons. Here, the diagnostic ability of the 
test is established by a "quick and dirty" method, i.e. the test is carried out in an 
easily accessible population. An easily accessible population could, for instance, be 
a population of diagnosed patients and healthy individuals. We are not concerned 
with the occurrence of selection bias or other problems at this point. 
If a test does not have sufficient discriminative power in this phase of 
diagnostic test assessment, which is not uncommon, the assessment procedure can 
be stopped. The test obviously needs further development. 
Test application in the indicated population 
This essential assessment phase of the "indicated" population should take place in a 
population of patients who are judged eligible for the new test in a real clinical 
situation because of the suspicion that they have the illness at issue. In this phase, 
therefore, we are concerned with the selection of the relevant patient population. 
Adequate selection of patients is achieved by gathering a consecutive series of all 
as yet undiagnosed patients with a suspicion of having the disease at issue on the 
ground of their complaints, signs and symptoms. 
Diagnostic profile 
In this phase it is clear that the new test has sufficient diagnostic power of its own, 
otherwise it would have been rejected in the study of the indicated population, i.e. 
patients with an indication for the application of the test in clinical practice. Now 
it is important to establish the contribution of the new test to the existing 
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diagnostic arsenal, including other diagnostic tests, the non-clinical profile (e.g. 
age, gender), the clinical profile (signs, symptoms and complaints) and 
comorbidity. If the new test cannot add diagnostic power to the existing arsenal, it 
should be questioned seriously whether introduction of the test into clinical 
practice is desirable. In this phase, it is also necessary to study only patients of the 
proper indicated population. In order to obtain the diagnostic information of the 
new test alone, the outcomes of all other diagnostic tests in use have to be known 
as well, which necessitates the concurrent measurement of those tests. 
Medical technology assessment 
The last challenge for the new test is a medical technology assessment, including 
selection and order of diagnostic tests, cost-effectiveness, patient's utilities or 
preference measurements, etc. The new test can perhaps be used as the first test 
after the history has been taken and physical examination has been carried out. 
However, it is also possible that the new test is so expensive that it is not justified 
to apply it to all patients, for example in cases where the natural course of the 
disease is not life-threatening. In this phase, questions of therapeutic efficacy (did 
treatment change), patient outcome efficacy (did life expectancy improve) and, if 
possible, societal efficacy (are costs acceptable for society) should be answered.12 
Because there are so many questions involved in the final phase of test 
assessment, the best way to deal with them is probably to carry out a clinical trial 
in the indicated population, with randomized allocation of the new test. 
What knowledge is needed? 
Before test assessment can actually be carried out in any study population, 
information has to be made explicit and should be stated clearly. First, the 
population in which the test is assessed should be carefully defined. Are already 
diagnosed patients and healthy controls to play a role in the study or are patients 
with suspicion of the disease at issue to be investigated? Also, the eventual 
realization of the study population has to be described, while indicating whether 
the investigators succeeded in gathering all consecutive patients or not. 
Secondly, the diagnostic test must be described clearly, which includes 
specifying the type of results it yields. Test results may be measured qualitatively 
or quantitatively. Many tests are in fact quantitative, but have been converted to 
qualitative tests. Pregnancy tests, for instance, measure the concentration of human 
chorionic gonadotropin (HCG) in the urine quantitatively, but have been converted 
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to qualitative tests that simply change color at a certain concentration of HCG. If 
tests are inherently qualitative, it is possible to assign a judgement probability of 
disease being present to the test result in order to create a quantitative test result. 
The more detailed the information that is gathered, the better the new test can be 
judged. Sometimes, a judgement of the test result comes from different observers, 
as when photographs are read by the staff member on duty. In this case, 
judgements should be standardized to eliminate inter-observer variation as much as 
possible. If an apparatus is simple to read, inter-observer variation may not be a 
problem, but systematical measurement errors of the apparatus should be known 
for the machine to be calibrated as often as is necessary. 
Finally, it should be stated for all patients in the investigation how disease 
status is verified. Sometimes all patients can be subjected to the golden standard, 
but for ethical reasons often clinical follow-up for a restricted period of time must 
be used as the criterion, at least for a part of the study population, in particular 
patients with negative test results. Occasionally, judgement relies on the 
prescription of and the subsequent reaction to a medication, for instance a certain 
pharmaceutical. 
All relevant patient characteristics, test results, and the ultimate diagnosis 
should be registered individually, including missing data. 
Statistical analyses 
There are different approaches to handle the diagnostic test results from an 
assessment study. For qualitative tests, measuring the test result on a 
presence/absence scale, sensitivity and specificity are the most commonly used 
measures for test performance. These test characteristics can be calculated when 
the data are presented in a fourfold table, such as Table 1. Currently, the 
presentation of the diagnostic information using likelihood ratios, also to be 
calculated from a fourfold table, is advocated more widely.13 Finally, there is a 
tendency to present the prevalence of illness in the groups of test results,14 since 
this is the proportion we are naturally interested in: if the test is positive, or 
negative, what is the probability that disease is present? If the prevalence of the 
disease is not relevantly higher in the group with positive test results than in the 
group with negative test results, the test provides little or no diagnostic 
information and should not be applied. 
For quantitative tests, with test results in more than two ordinal categories or 
on a continuous scale, it is recommended to present all the information they 
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provide. Dichotomization for the calculation of sensitivity and specificity is 
unnecessary, since Receiver Operating Characteristic (ROC) curves13 and 
cumulative probability distributions16 can be made. Figure 1 gives an example of 
cumulative distributions of ultrasonographically measured pyloric muscle thickness 
in patients originally suspected of having hypertrophic pyloric stenosis (HPS), 
presented separately for patients with and without the disease (Chapter 10). 
Cumulative frequency distributions provide clinicians with the sensitivity and 
specificity of a test at any cut-off point requested. 
An ROC curve displays sensitivity versus 1 minus specificity at a large number 
of cut-off points.1317 ROC curves are independent of cut-off points and yield the 
area under the curve (AUC) as a summary measure of diagnostic performance. 
Furthermore, different tests assessed in one population can easily be compared and 
the ROC curve is relatively stable to verification bias.' Figure 2 shows an ROC 
curve for the same data on pyloric muscle thickness in patients with and without 
HPS as mentioned above. 
Prevalence of disease can be calculated for patients with a positive test result 
and for patients with a negative test result, as well as for the various categories of 
test results for a quantitative test. Figure 3 shows the prevalence of HPS for 
categories of pyloric muscle thickness. In the case of a perfectly discriminating 
test, prevalence in the lower categories of pyloric thickness would be zero, 
whereas the prevalence of HPS in the higher categories of pyloric muscle thickness 
would be one. If the prevalence of disease conditional on clinical and non-clinical 
profile, comorbidity and other diagnostic test results is required, logistic regression 
analysis is the appropriate way of estimating it." Table 2 shows the prevalence 
function of HPS. According to the presence or absence of a feature or the result of 
a diagnostic test for an individual patient, data is substituted in the prevalence 
function, and the probability of having the disease can be calculated. 
As in all analyses, missing values on test outcome or disease status have to be 
dealt with properly, for instance as a separate category, rather than be removed 
from the analyses and wholly disregarded.19 
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Illustration 
To illustrate current practice of diagnostic test evaluation, and to support the 
formulation of new guidelines for assessment studies, we reviewed publications on 
ultrasound in the diagnosis of idiopathic hypertrophic pyloric stenosis. HPS is an 
obstruction of the gastric outlet that occurs in two per 1000 live births. Its etiology 
has not been resolved yet. HPS manifests as progressive spasms from 
approximately three weeks after birth, followed by projectile vomiting. Patients 
lose weight without losing appetite. Traditionally, the diagnosis is made when an 
olive-shaped mass is palpable in the abdomen. If no mass is felt, radiology with 
barium as the contrast medium is used for diagnosis. The first description of 
ultrasonography dates from 1977.a The method is believed to be useful when 
classical clinical investigation and radiography fail. 
In order to learn the assessment route of ultrasound (US) we selected reports 
published in English via a MEDLINE search and through carefully checking 
references in the selected reports. The search procedure resulted in 23 papers 
suitable for our purpose. The studies were classified according to type of 
assessment phase and are presented as such in Table 3. It is remarkable that no 
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Table 3 Studies of ultrasound in the diagnosis of idiopathic hypertrophic pyloric 
stenosis, classified according to assessment phase 
Assessment Phase 
Test development 
"Easy population' (diseased vs. healthy) 
"Easy population" (selected diseased and 
nondiseased persons) 
"Indicated population" 
'Diagnostic profile" 
"Medical Technology Assessment" 
Number of 
studies 
reviewed 
6 
3 
11 
2 
0 
0 
References 
20, 27, 28, 29, 32, 
41 
30, 31, 35 
23-26, 33-40, 42 
21,22 
-
-
studies could be found that were to be classified into either the "diagnostic 
profile" or the "medical technology assessment" phase. Ultrasound has 
nevertheless become a standard tool in today's diagnosis of hypertrophic pyloric 
stenosis. 
After the first description of the possible value of US in the diagnosis of HPS 
in five babies.20 US was soon evaluated in larger patient series. Table 4 lists the 
elements of population, test results or disease verification that, according to our 
guidelines, should have been included in the various sections of the papers 
describing evaluation studies. Obviously, in earlier days many of these elements 
were not considered worth mentioning or even necessary to work out in study 
design and analysis. 
Although many authors describe their patient sample as a collection of patients 
suspected of having HPS, a great part of them also include patients with a clearly 
palpable olive-shaped mass, which is known to be pathognomonic for HPS. It still 
remains unclear whether ultrasound is of value for patients in whom no masses can 
be felt. More adequate assessment could probably have prevented this uncertainty. 
Furthermore, it is often not mentioned whether the HPS is of the congenital or 
the evolving type. This has implications for diagnosing HPS, since for patients 
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Table 4 Elements of study design not adequately described m papers concerning 
ultrasound-HPS studies with an "Easy population ' (selected diseased and non-
diseased persons) 
Elements of study design References 
Population 
- Not presented or no consecutive senes of suspected 23-26, 34, 38, 42 
patients 
- Patients with palpable masses included or inclusion not 23-26, 33, 34, 38-40, 42 
given 
- Lack of definition of suspicion 22, 24, 34, 36, 38, 40, 42 
Test results 
- No calculation of sensitivity, specificity, false negative 
or positive rate 
- No distnbution(s) shown 
- Lack of calculation of prevalence for categories of 
ultrasound result 
23, 33, 34, 37-39 
23, 24, 33, 34, 36, 38 
23, 24, 26. 33, 34, 36^(0 
Disease verification 
- Verification method not stated 
- Only part of test-negatives verified with surgery, 
radiography (or palpation) 
24, 26, 38, 40 
23, 25, 33, 39, 42 
with evolving HPS, complaints have to be present for at least some time before the 
difference between normal and hypertrophied muscle can be seen. However, the 
duration of complaints is often not mentioned either. 
We were able to find only two papers that describe a real indicated population, 
with exclusion of patients with a palpable mass. One paper presented perfect test 
characteristics,21 in the other a sensitivity of 89% at a specificity of 100% was 
found.22 These findings were apparently convincing enough for US to be 
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incorporated in the diagnostic process of HPS. 
Conclusion 
Good guidelines for diagnostic test assessment could prevent the introduction of 
disappointing diagnostic tests before they are fully implemented in clinical 
practice. Although a phased assessment is not foolproof, it is highly likely that the 
chances of detecting a useless test are increased by introducing such an assessment 
procedure. This is aptly illustrated by the example of phased medical drug 
evaluation. 
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Problems in selecting the adequate patient 
population from existing data files 
Abstract 
Assessment of new diagnostic tests should be carried out in a population with 
disease suspicion. This "indicated" population may comprise all patients for whom 
the target disease is part of the differential diagnosis (DD). To investigate this 
empirically, data from a study on ultrasonography (US) for scrotal pathology 
diagnosis was used for assessment of US for epididymitis. The population was 
restricted from one comprising patients with epididymitis and/or epididymitis 
mimicking diseases, to one comprising patients with only epididymitis mentioned 
in their DD. The sensitivity of US deteriorated from 83% to 76%, the specificity 
from 97% to 79%. The prevalence of epididymitis for test-positive patients 
fluctuated closely around 90%, for test-negative patients it increased from 5% to 
56%, suggesting selection on the true disease status. We advocate prospective 
assessment studies in populations with disease suspicion, as defined by signs, 
symptoms and complaints, as the true disease status is still unknown at this stage. 
Selection of an indicated population from an existing file of retrospectively 
gathered data may pose problems. 
Prior to the introduction of a new test in routine clinical practice, its sensitivity 
and specificity are traditionally determined as validity measures.' Usually, test 
results of diagnosed patients are compared with those of healthy people. However, 
in clinical practice the test is used in patients with certain signs, symptoms and 
complaints to distinguish between presence and absence of disease. In such a 
patient population, "absence of disease" is often not equivalent to "healthy". Thus, 
the patient population in clinical practice differs from the study population on 
which test indices are initially based. This has major implications for the test 
indices, since these are dependent on the patient characteristics of the population in 
which they are determined.2 Accordingly, the study population should be 
constituted by patients suspected of having the disease which the test is supposed 
to diagnose, the so-called "indicated" population. An indicated population might 
comprise all patients whose differential diagnosis (DD) includes the target disease. 
Although this is easy to understand in theory, the selection of the indicated 
population in daily practice poses particular problems. In prospective studies it 
may be relatively easy to define the population eligibility criteria based on signs, 
symptoms, complaints, etc. However, the main disadvantage of these follow-up 
studies is the enormous amount of work that has to be carried out over a 
prolonged period of time before enough patients have been enrolled. It would 
therefore be convenient if existing data files could be used to select an indicated 
population. Unfortunately, in patient records, information on the presence of 
complaints, signs and symptoms is not reported consistently. The reason for 
testing, for instance, might be a useful criterion in selecting the adequate 
population, but in many cases such information is not registered, as has been 
noticed previously.2 We considered the DD as registered in routinely kept patient 
records a potential entrance to the indicated population, in which the diagnostic 
power of a test is to be studied. 
The diagnostic power of a test is expressed by its sensitivity, specificity and/or 
likelihood ratio of a positive or a negative test result (LR+ and LR-). As is well-
known, sensitivity and specificity, and thus LR+, are susceptible to bias, such as 
verification, diagnostic-review, test-review and incorporation bias.3,4 However, it 
has been shown that, as long as this bias occurs independently of the true disease 
status of the patient, the prevalence of disease in the test result categories remains 
unbiased.5* (See Figure 1) Therefore, we studied not only the sensitivity and 
specificity, but also the prevalence of disease for each test result category. Table 1 
shows the contingency table from which these ratios can be derived. 
The aim of the present study is to empirically investigate the effect of patient 
selection on the diagnostic power of ultrasonography for epididymitis. Data was 
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Sens = proportion of patients with a positive test result 
Spec = proportion of non-patients with a negative test result 
r+ = referral rate for patients with a positive test result 
r_ = referral rate for patients with a negative test result 
* denotes situation after referral 
Sens* > Sens, provided that r+ > r-
Spec* < Spec, provided that r+ > r-
Figure 1 Sensitivity and specificity of a diagnostic teu Τ in the original (Sens, Spec) and 
"referred" population (Sens', Spec') 
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Table 1 General contingency table for calculation of test parameters 
Disease 
Present Absent 
Test result 
Positive 
Negative 
a b 
с d 
b + d 
a + b 
с + d 
N 
Sensitivity proportion of diseased with positive test result = a/(a + c) 
Specificity proportion of non-diseased with negative test result = d/fb + d) 
Likelihood ratio of positive test result = al (a + c) b/(b + d) 
Likelihood ratio of negative test result = c/(a + c) d/(b + d) 
Prevalence of disease for test-positive patients = al (a + b) 
Prevalence of disease for test-negative patients — c/(c + d) 
available from an assessment study of US for scrotal pathology7 The data 
comprised the US test results and the differential and final diagnoses and thus 
provided the opportunity to select patients according to their DD 
Materials and methods 
Enrolled in the original study were 483 consecutive patients with clinical suspicion 
of scrotal pathology, referred to the Department of Diagnostic Radiology of the 
University Hospital in Nijmegen by urologists and pediatric surgeons Information 
on differential diagnoses, the final diagnoses and the ultrasonography results was 
available from the medical records for 411 patients, who were included in the 
present study In nineteen patients the disease was considered to be cured at the 
time of the ultrasonography For the purpose of clarity, these patients were 
excluded from all analyses Twenty patients had had an epididymectomy or an 
epididymo-orchidectomy in the past and were also excluded from the analyses, 
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since in these patients epididymitis can neither occur nor be a serious 
consideration. Final diagnoses were confirmed by clinical follow-up (78.2%), 
histological examination (11.0%), during surgery (8.1%) or by phlebography 
(2.7%). 
Epididymo-orchitis and epididymitis were regarded as the same disease entity 
and indicated as epididymitis in this paper, because the difference is often difficult 
to perceive. Epididymitis is seen as a precursor of epididymo-orchitis and the 
therapeutic consequences are the same.' 
To investigate the influence of patient selection on the diagnostic power or 
performance of ultrasound, patients were selected according to varying criteria. 
Initially, the study group comprised all available patients (n=382), i.e. including 
patients who were not particularly suspect of having epididymis pathology. In a 
second step, patients with a broad selection of pathology which might mimic 
epididymitis were selected. This study group consisted of patients with a DD 
including epididymitis, epididymo-orchitis, testicular torsion, testicular carcinoma, 
spermatocele, hydrocele, orchitis, testis or epididymis abscesses. In a third step, 
patients with only epididymitis, epididymo-orchitis, testicular torsion or testicular 
malignancy explicitly mentioned in the DD were selected, for the latter two are the 
pathologies that are most frequently misdiagnosed as epididymitis. Finally, a 
narrow selection of patients with just epididymitis or epididymo-orchitis as one of 
the differential diagnostic considerations mentioned at referral were selected. For 
each selected patient group, the sensitivity, specificity and LR+ of US, and the 
prevalences of epididymitis for patients with positive and negative US results were 
calculated. 
Results 
A total number of 382 scrotal diseases were investigated in 382 patients. Age 
ranged from 0 to 78 years, mean age was 38 years (SD 16 years). Mean ages were 
different for various diagnostic categories. Table 2 presents final diagnoses in the 
population. 
Table 3 shows, for the different selections of patients, the prevalence of 
epididymitis, the sensitivity, specificity, and prevalences of epididymitis for 
patients with positive and negative US results. The prevalence of epididymitis and 
epididymo-orchitis increases with increasing severity of the population restriction. 
It is visible that with an increasingly severe restriction of the population, the test 
properties change markedly. The traditional parameters of sensitivity and 
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Table 2 Final diagnoses for all 382 problems in the patient population 
Problem 
No abnormalities 
Scrotal edema 
Scrotal lymphedema 
Other scrotal pathology 
Hydrocele 
Haematocele 
Testis m inguinal channel 
Testis atrophy 
Testis infarction 
Orchitis 
Epididymo-orchitis 
Primary testis tumor 
Testis lymphoma 
Testicular torsion 
Testiculith 
Other testicular abnormalities 
Epididymitis 
Epididymis abscess 
Epididymis cyst 
Other epididymis abnormalities 
Appendicular torsion 
Varicocele 
Intrascrotal space taking process 
Haematoma 
N 
114 
1 
1 
2 
28 
1 
3 
10 
2 
6 
9 
17 
1 
8 
1 
11 
79 
4 
38 
3 
6 
29 
2 
4 
Subtotal 
114 
4 
29 
68 
124 
42 
Table 2 Continued 
Problem N Subtotal 
Other 2 43 
Total 382 382 
Table 3 Sensitivity (Sens), specificity (Spec), LR+ and prevalence (Prev) of epididymitis 
for test-positive (Prev+) and test-negative (Prev-) patients regarding 
ultrasonography for epididymitis in different selections of patients 
Selection Prev Sens Spec Prev Prev- LR + 
All patients (n = 382) 23% 83% 97% 89% 5% 28 
Epididymitis, epididymo-orchitis, 
testicular torsion, testicular 
carcinoma, spermatocele, hydro-
cele, orchitis, testis or epididymis 
abscesses in differential diagnosis 
(n = 183) 
39% 81% 95% 91% 12% 16 
Epididymitis, epididymo-orchitis, 
testicular torsion or testicular 
carcinoma m differential diagnosis 
(n = 108) 
Epididymitis or epididymo-orchitis in 
differential diagnosis (n = 73) 
57% 77% 87% 89% 26% 
81% 76% 79% 94% 56% 
specificity both deteriorate The sensitivity decreases from 83% to 76%, and 
specificity decreases from 97% to 79% The LR+ decreases considerably from 28 
to 4 In our data the prevalence of epididymitis for test-positive patients remains 
fairly stable at approximately 45% The prevalence of epididymitis for test-
negative patients changes most notably, increasing to ten times the original value, 
from 5% to 56% 
Discussion 
The presented results show that different procedures in patient selection for 
assessment studies can result in substantial differences in the outcome of the 
assessment. It might be expected that the prevalence of the disease will increase 
with each referral step. However, not only the prevalence in the patient population 
changes, but so does the composition of the patient groups with respect to their 
symptoms and signs, disease severity and diagnostic test results. So, the often 
described model postulating a constant sensitivity and specificity of a test is clearly 
too simple an interpretation of the situation. This phenomenon has already been 
recognized by various authors,3·910 yet few investigations into the influence of 
patient selection on assessment outcome have been carried out in clinical practice. 
As mentioned before, selection of patients for referral or disease verification 
that is only dependent on diagnostic test results or symptoms and is independent of 
the true disease status only results in changes of the sensitivity and specificity, one 
increasing at the expense of the other, whilst the predictive values of the test or 
the disease prevalences in various test result categories remain constant.'·6 An 
illustration of this is given in Figure 1. As patients with positive test results are 
more likely to be referred, sensitivity and LR+ generally increase whereas 
specificity and LR- decrease/ 
What we see happening in our empirical data is a change of almost all test 
characteristics. The deterioration of the specificity is in accordance with the theory 
of selection based exclusively on test results or symptoms, as is the constancy of 
the prevalence of epididymitis for patients with positive test results. However, the 
sensitivity also decreased, which was not to be expected from this theory but is 
suggestive of selection on the true disease status of patients, as is the increase of 
the prevalence of disease for patients with negative test results. From the results it 
appears that patients with positive test results were selected independently of their 
true disease status, whereas patients with negative test results were selected on the 
basis of their true disease status, namely based on the fact that they actually had 
epididymitis. This is illustrated in Table 4, which shows the percentage of selected 
patients from each cell of the original fourfold tables and for each step in the 
selection process. 
What might have happened with the patients in the present study is that patients 
with clear, or positive signs, symptoms or test results were directly selected for 
entrance in the large study of US assessment for scrotal pathology. Patients with 
less clear, or negative features will have received normal clinical care. Probably, 
for a number of them clinical follow-up will have shown that they were yet 
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suffering from some scrotal disease. So their DD will have been adjusted, or now 
for the first time a DD-list will have been made, and they will also have been 
selected for the study. 
The consequences of such selection patterns for assessment studies are obvious. 
Unfortunately, this study makes it unlikely that retrospective selection of an 
indicated population that comprises patients suspected of having the disease at 
issue, can be reliably made on the basis of the differential diagnosis. In the 
original investigation, it was tried retrospectively to gather information on clinical 
symptoms, signs, physical examination and results of other diagnostic tests. 
However, in the patient records this information was not reported consistently. 
This problem is often encountered in studies using data that are routinely gathered 
in clinical practice. Some practitioners report both the presence and the absence of 
patient characteristics, others report only their presence. Moreover, there is no 
standardized protocol indicating which characteristics are important to document 
for which disease. 
In conclusion, assessment studies in an indicated population should be 
prospective studies, because the selection of the population cannot be made 
reliably from existing data, unless signs, symptoms and complaints are gathered 
consistently. Such a method of data gathering will be very difficult to implement 
in daily clinical practice because of the amount of work involved. 
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ROC curves for the initial assessment of new 
diagnostic tests 
Abstract 
New diagnostic tests are mainly evaluated by determining the sensitivity and 
specificity of the test. These test characteristics were originally meant to be used in 
making diagnoses. For evaluative purposes their usefulness is weakened by their 
susceptibility to selection and their dependence on the cut-off points that are used 
for test positivity. The plotting of a Receiver Operating Characteristic (ROC) 
curve might be a solution to these problems. Furthermore, the ROC curve yields a 
measure for the diagnostic power of the test expressed in one number instead of 
two, namely the area under the curve (AUC). Finally, the ROC curve and its 
AUC permit easy comparison of different tests and the performance of different 
interpreters of one test. 
The construction and use of ROC curves are described and illustrated with data 
of a case-referent investigation into the relationship between iron status parameters 
and the presence of acute myocardial infarction. The AUCs of ferritin and serum 
iron, 0.61 and 0.68 respectively, are too low to suggest meaningful usefulness in 
clinical practice. 
Generally, new diagnostic tests are initially assessed by calculating the sensitivity 
and the specificity, and sometimes also the likehood ratio. Papers presenting such 
data can also be found in family practice journals.1 
The sensitivity and specificity are important parameters in making diagnoses, 
because it is possible to calculate the probability of a disease being present in a 
particular patient from the prior probability of disease and sensitivity and 
specificity.2 Thus, sensitivity and specificity are useful measures for diagnostic 
purposes. 
The usefulness of the sensitivity and specificity for the purpose of evaluating 
diagnostic tests, however, is weakened by the fact that different investigators 
present different test characteristics for the same test.3 This is due, among other 
things, to the use of different cut-off points for a positive test result, which results 
in varying sensitivities and specificities. Furthermore, the distributions of the test 
results for patients and non-patients can vary considerably among studies because 
of selection phenomena. For the evaluation of diagnostic tests it is of vital 
importance to use a parameter that is invariant relative to cut-off points and 
selection. The Receiver Operating Characteristic (ROC) curve, an easily 
interpretable figure, provides such a parameter, expressed in one figure, 
independent of cut-off points and reasonably invariant to selection.4 If, and only if 
the diagnostic power of a test is considered to be good, the cut-off point which is 
clinically most relevant can be determined. In the present paper the construction 
and the use of the ROC curve will be explained using one general example. 
General example 
In 1986-1988, a case-referent investigation was conducted into the aetiological 
relationship between the iron status (ferritin, serum iron, transferrin, iron 
saturation of transferrin) and the presence of a first acute myocardial infarction 
(AMI).3 The outcome of this study led to the hypothesis that ferritin might be of 
diagnostic value for the AMI. Ferritin was found to be released in the acute phase 
of the infarction and to be present in high concentrations in the serum of AMI 
patients, whereas the referents had normal serum ferritin concentrations. The 
opposite observation was made for serum iron. 
Patients and methods 
Data were gathered in the Zuiderziekenhuis hospital in Rotterdam, The 
Netherlands, in 1986-1987. To be eligible for enrollment in the study, the 
50 Chapter S 
consecutively diagnosed AMI patients and the population referents had to meet 
several inclusion criteria, which are summarized in Table 1. 
Eighty-four patients were eligible. From the municipal register of the city of 
Rotterdam referents were randomly selected and matched to the cases for gender 
and age (five-year interval). Eighty-four referents were enrolled. Venous blood 
samples were obtained from the patients upon admission, i.e. within four hours of 
onset of first symptoms. Blood samples were obtained from the referents at their 
homes within two months of the time of selection of the case to whom they were 
matched. 
Table 1 Inclusion criteria for patients with a first acute myocardial infarction (AMI) and 
population referents 
AMI patients Population referents 
Normal diet 
No treatment for kidney or lung disease 
No treatment for alcohol or drug abuse 
Age under 75 years 
No chronic heart diseases 
Elevated serum creatmekinase 
Elevated serum aspartate amino-
transferase 
Specific ECG abnormalities 
No cardiac complaints longer than six 
months prior (o the event 
Normal diet 
No treatment for kidney or lung disease 
No treatment for alcohol or drug abuse 
Age under 75 years 
No history of heart failure 
Serum ferritin was measured by the enzyme immunoassay method of Addison 
et al as modified by Miles et al.* Serum iron was estimated as described by 
Eskelinen et al.7 
Distributions οΓ test results 
Not all patients with a certain disease will have the same test results. Some results 
occur frequently, other results, such as extremely high or extremely low results, 
occur less frequently.' Figure 1 depicts the distribution of serum ferritin 
concentrations for the AMI patients. 
The frequency of occurrence of the various ferritin levels is expressed in 
percentages of the total number of patients in the investigation. 
For patients without the illness at issue (the referents) a frequency distribution 
can be made as well. In the case of a good diagnostic test there will be hardly any 
overlap in the distributions of patients and referents respectively. The overlap of 
test result distributions, which occurs in almost any diagnostic test, may be 
explained by the natural distribution of biological substrates in humans. Ferritin is 
also present in the serum of healthy persons. However, the determination of the 
ferritin level would be a useful diagnostic test if ferritin levels were strongly 
elevated in the sera of AMI patients. 
Furthermore, the overlap of distributions of test results depends on the 
composition of the population under investigation.' Suppose that technetium 
pyrophosphate scintiscan for the diagnosis of myocardial infarction is evaluated. If 
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Categories of ferritin (ng/ml) 
Figure 1 Percentual frequency distribution of the 84 patients with a first acute 
myocardial infarction, according to categories of ferritin 
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the study population consists, on the one hand, of patients with a typical history of 
myocardial infarction and with ECG changes of transmural infarction and clear-cut 
elevations of the MB isoenzyme of creatine Phosphokinase (MB-CPK) and, on the 
other hand, of medical students, little overlap will occur in the test results. This 
will not be the case, however, if the first group comprises patients with non-Q-
wave infarctions and borderline elevations of MB-CPK and the second group 
comprises patients with old infarctions and unstable angina pectoris. 
Cut-off points 
In daily clinical practice, a cut-off point is used for diagnostic tests, for example a 
normal level. Below this level the result of the test is negative, in other cases the 
test result is positive. Such dichotomization is inherent to a doctor's medical 
behaviour: the diagnostic process is complete or not, a certain treatment is given 
to a patient or not.10 
If a cut-off level of 50 ng/ml is chosen for ferritin, 84.5% of the AMI patients 
have a positive test result (Figure 1). This percentage is the sensitivity of the test. 
Further, 81% of the referents have a positive test result as well, i.e. the test has a 
false positive fraction of 81%, or, in other words, a specificity of 19%. Figure 2 
shows the distribution of ferritin for AMI patients as well as for referents. 
The choice of another cut-off point will result in different values of the sensitivity 
and specificity of ferritin for AMI. If the cut-off point in Figure 2 is moved to 100 
ng/ml, or even 200 ng/ml, the specificity increases to 59.5% and 89.3%, whereas 
the sensitivity decreases to 58.3% and 22.6%, respectively. Obviously, 
sensitivities and specificities from various investigations are not always comparable 
straight away. 
The ROC curve 
Tabulating the entire range of sensitivities and specificities at the various cut-off 
points would be a solution to the problem of different cut-off points and, 
consequently, different test characteristics. However, such a series of numbers 
would be inconvenient to work with. A more practical solution is to plot the 
numbers in a graph, the Receiver Operating Characteristic (ROC) curve.10"12 In 
such a curve the sensitivity is graphed on the Y-axis against the false positive 
fraction (specificity) on the X-axis. 
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Figure 2 Percemual frequency distribution of the 84 patients with a first acute 
myocardial infarction (AMI) and the 84 population referents, according to 
categories of ferritin. Categories of percentage of total number of patients and 
total number of referents. The X-axis is marked in the centre of the categories; 
first category 0-49. etc 
An ROC curve for ferritin is constructed as follows. Sensitivities and specificities 
are calculated for the cut-off points A, B, and С as indicated in Figure 2. Next, 
the sensitivities and the complement of the specificities are plotted in Figure 3. 
The cut-off point 50 ng/ml (sensitivity 84.5%, specificity 19%) corresponds to 
point A on the ROC curve, while the cut-off points 100 ng/ml (sensitivity 58.3%, 
specificity 59.5%) and 200 ng/ml (sensitivity 22.6%, specificity 89.3%) 
correspond to points В and С respectively. 
For a nondiscriminating test the distributions of results for patients and 
referents will show complete overlap, and accordingly, at each cut-off point the 
sensitivity (true positive fraction) will equal the complement of the specificity 
(false positive fraction). The resulting ROC curve coincides with the diagonal. The 
result distributions of patients and referents will hardly show overlap for a good 
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Figure 3 ROC curve for serum ferritin for 84 patients with a first acute myocardial 
infarction (AMI) and 84 population referents. A: cut-off point 50 ng/ml; B: 
cut-off point 100 ng/ml; C: cut-off point 200 ng/ml 
test and in that case the ROC curve will be moved to the upper left corner of the 
diagram.10 
ROC curves demonstrate the discriminating power of a diagnostic test; the 
further the curve is in the upper left corner, the better the test. The area under the 
curve (AUC) is a measure of the diagnostic power of a test.13 A test which does 
not discriminate between ill and non-ill people will have an AUC of 0.5 under the 
diagonal. A perfect test will have an AUC of 1.0. The calculation of the AUC is 
described in more detail in the appendix. 
The AUC of the ROC curve of ferritin was 0.61 with a 95% confidence 
interval (CI) of 0.51-0.70. Since this is rather low, it does not seem to be useful 
for diagnostic assessment of serum ferritin concentrations in patients suspected of 
having myocardial infarction. 
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Comparison of several tests for one disease 
New tests for the diagnosis of a certain disease are introduced regularly. ROC 
curve provides the possibility of comparing the diagnostic powers of two or more 
different tests at one glance. Ferritin turned out to be a disappointing diagnostic 
test for AMI. In the case-referent investigation, also serum iron concentrations 
were determined. An ROC curve can be constructed for serum iron as well. 
Figure 4 shows that serum iron has a slightly better diagnostic power than ferritin. 
The AUC of 0.68 (95% CI 0.60-0.76) nevertheless indicates that serum iron is not 
useful for diagnostic purposes either. 
The differences between AUC's can be tested for statistical significance, as 
explained at length by Hanley." For mathematical details we refer to the appendix 
of this paper. 
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Figure 4 ROC curve for serum ferritin and serum iron for 84 patients with a first acute 
myocardial infarction (AMI) and 84 population referents. Ferritin: AUC=0.61, 
95% CI 0.51-0.70, Serum iron: AUC=0.68, 95% CI0.60-0.76 
Tests with positive/negative results; inter-observer variation 
So far, tests have been considered with several result categories. However, an 
ROC curve can also be plotted for tests with just a positive or negative result. An 
example of such a test is the Dutch national screening programme for breast 
cancer.11 The test is mammography and the result is yes/no suspicion of 
malignancy. The radiologist might express the degree of certainty he or she 
attributes to the diagnosis as a percentage, e.g. 100% if a malignant tumour is 
present with certainty and 0% if no malignancy is present with certainty. The 
more uncertain the radiologist is about the diagnosis "malignancy present", the 
lower the designated percentage. The scores can be divided into categories and an 
ROC curve can be constructed again. 
All reviewers of test results will not judge in exactly the same way. This leads 
to inter-observer variation in the judgement of test results. Good agreements on 
when a test result is to be considered positive or negative will lead to more 
consistent judgements among different reviewers. The presence and extent of 
discrepancies in the judgement of different observers can be studied with ROC 
curves. Discrepancies between observers may result from true discrepancies in 
assessment power. On the other hand, one observer may consistently score higher 
percentages than another observer for the same images. This results in an 
increased "sensitivity of the first observer", at the expense of "his specificity" (not 
only the fraction of true positives increases, but also the fraction of false 
positives). The curve of the ROC plot will be the same for the first and the second 
observer, the individual points will be shifted to the right. 
Another relevant phenomenon is intra-observer variation, which means that the 
judgements of one investigator may also show discrepancies over time. The more 
experience an investigator acquires in judging test results, the further his ROC 
curve will move toward the upper left corner of the diagram. The Dutch National 
Reference Centre for Breast Cancer Screening uses ROC curves to monitor the 
progression of radiologists during training."1 
General considerations 
The combination of one sensitivity and one specificity turned out to be an 
inadequate measure for the evaluation of diagnostic tests. The combination depends 
on the cut-off point for test positivity, chosen by the investigators. The 
presentation of an entire range of sensitivities and specificities at various cut-off 
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points results in better comparibility of diagnostic tests. To provide a convenient 
lay-out, the range is presented graphically in an ROC curve. The area under an 
ROC curve, the AUC, is a measure for the diagnostic power of a test, independent 
of cut-off points. With the AUC, tests for a certain disease can easily be 
compared. Furthermore, the diagnostic power of different interpretations of one 
test or the progression of one interpreter over time can be compared by means of 
AUCs. 
Selection may lead to different distributions of test results for diseased and non-
diseased persons in different investigations. In any case, this will lead to different 
values of sensitivity and specificity. However, the ROC curve seems reasonably 
insensitive to selection.4 The shape of the ROC curve and its AUC will be stable, 
while the individual points of sensitivity and specificity move along the curve with 
respect to the unselected situation. 
Only if thorough evaluation studies result in a test that is ready for use in 
clinical practice, is it worthwhile to determine the cut-off point for positivity that 
is to be used in daily practice. This cut-off point will vary according to the 
situation in which the test is used. A specialist's centre will set different 
requirements to the test than a general practitioner (GP) will, because in the 
Netherlands, as well as in Great Britain and Canada, GP's are a sieve for further 
specialist care and therefore populations are different. 
The analogy between diagnostic test evaluation and effectiveness studies of new 
pharmaceutical agents can hardly be denied. In the case of medical drugs, several 
phases of investigation have to be completed with success before access to the 
market is permitted. For new diagnostic tests a phased evaluation could be 
considered as well. The selection of a suitable patient population for each phase is 
important for a valid evaluation of the new test.17 
For an initial assessment of a test, an easily accessible patient group will 
suffice, such as diagnosed patients and healthy persons. It is important, though, 
that the composition of the study population is accurately described, in order to 
facilitate reading and comparison for other investigators. The ROC curve of the 
new test should be assessed. The AUC should be reasonably high in this 
population, otherwise the evaluation procedure can be stopped: the new test is 
clearly not ready yet for implementation. 
The initial phase can also be characterised by the intentional search for the 
parameter that yiels the best measuring results. Ferritin and serum iron proved to 
be of no value for the diagnosis of AMI, while transferrin or a composition 
parameter such as iron saturation of transferrin could be more useful. 
For the second phase of initial assessment one should turn to the future patient 
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population of the test; i.e. people suspected of having the illness at issue. In that 
case it is necessary to have a random sample of the entire domain of persons 
available for the investigation. Co-operation with other hospitals could be 
considered for gathering a sufficient number of patients. 
If the results of the initial assessment phases are satisfactory (high AUC), the 
extensive phase three can be started, i.e. the assessment of the new test's place in 
the entire diagnostic arsenal. Besides the results of the new diagnostic test, 
determined in the domain population, the information on all other diagnostic tests 
is of importance as well in this phase. Other diagnostic tests include anamnesis, 
physical tests, routine laboratory tests, specific X-ray investigations, functional 
tests, etc. Multivariate statistical techniques may be used to determine the 
diagnostic power of each test. 
At this point in the evaluation of a new test a medical technology assessment 
(phase four) should be performed. Some tests, for instance invasive, dangerous or 
expensive tests, might be left out of the arsenal without negative effects on the 
diagnostic capability. With the neverending input of new diagnostic tests, it is 
reasonable to let them pass the abovementioned phases of evaluation, prior to 
acceptance or registry of the tests. ROC analysis is particularly suitable for 
analysis in the first two phases. 
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Appendix 
Sensitivities and specificities of test results have to be calculated at various cut-off points in 
order to be able to construct an ROC curve. For this purpose, test results are divided into 
categories of which the boundaries can be chosen so that an approximately normal 
distribution results, for the patients as well as for the referents. In some cases, a 
transformation might be necessary, e.g. a logarithmic transformation. 
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The general equation for the statistical paired t-test of differences between two AUC's 
for two different tests, derived from the same population, is as follows: 
AVCX - ЛиСг 
pE¡ * SE%) 
where SE represents the standard errors of the AUCs. If ζ exceeds a given limit of the 
normal distribution, e.g. 1.96 with a significance level of 5%, then it is concluded that the 
AUC's truly differ from each other. However, the two AUCs are probably correlated 
because they are derived from the same patients. It is necessary to incorporate a correction 
factor into the difference of the standard errors, which results in the following equation: 
AUCt - ЛиСг 
J(SEI * SE¡ - 2rSElSE^ 
The necessary correlation coefficient г vanes, depending on the AUCs and can be 
calculated from the original publication of Hanley and McNeil.14 
The AUC of an ROC curve can be calculated using the trapezium method." A diskette 
with software is available from the authors. 
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ROC curves and their AUCs of dichotomized tests 
with normally and logistically distributed results 
Abstract 
Many measures exist for the assessment of diagnostic tests, such as sensitivity and 
specificity, predictive values, likelihood ratios, etc. A drawback of these measures 
is that continuous test results are often dichotomized, with, consequently, loss of 
information. Receiver operating characteristic (ROC) curves do not depend on 
discrimination thresholds, and therefore the area under the ROC curve (AUC) is 
one of the preferred. Unfortunately, quantitative test results are often presented 
dichotomized and it would be convenient yet to be able to estimate ROC curve and 
AUC. Here we present equations for these estimates when only one pair of a true 
and a false positive rate is given, for inherently logistically and normally 
distributed data. The paper is illustrated with empirical data of both distributions. 
In contradiction to what was reported earlier, we also show that differential disease 
verification may influence the ROC curve seriously. The ROC curve is thus not 
invariant to selection bias. 
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A confusing number of statistical measures for the diagnostic performance of tests 
is available, nowadays. The use of sensitivity and specificity is widespread1 and 
recently the use of likelihood ratios and predictive values is more and more 
advocated.2 Occasionally, the odds ratio is used as a measure of diagnostic test 
performance. It is even possible to estimate a chance-adjusted sensitivity and 
specificity.3 However, all aforementioned parameters depend on the arbitrary 
choice of a discrimination threshold for test positivity in case of continuous test 
results. The use of the Receiver Operating Characteristic (ROC) curve is a solution 
to this cut-off point dependency, as an ROC curve shows the relationship between 
the sensitivity and the complement of the specificity as the discrimination threshold 
is changed. Because of the independency of the prior probability of disease and of 
the arbitrary choice of a discrimination threshold and the insensitivity to 
monotonous transformations, the area under an ROC curve (AUC) is considered 
an attractive index of diagnostic performance. 
Frequently, one pair of sensitivity and specificity is the only measure of 
diagnostic information content of a test that is presented, often without even 
mentioning the discrimination threshold used. Recently, Diamond described an 
ROC curve that may be estimated using the true and false negative rate at any 
particular decision threshold, no matter which threshold is chosen.4 For this 
purpose, a hyperbolic transformation was employed to the chosen pair of true and 
false positive rate of the diagnostic test results. Diamond showed that the resulting 
ROC curve is identical to that derived from two logistic distributions with equal 
variance. 
Besides for the ROC curve of two logistic distributions, also an equation for its 
AUC can be derived. Furthermore, a comparable estimate for the ROC curve and 
the AUC of normally distributed data can be derived. 
Diagnostic test assessment requires disease verification and at this point often 
verification bias occurs. Patients with positive test results are more likely to be 
referred for disease verification than patients with negative test results, often for 
ethical reasons. As a result, disease can be missed for the non-referred test-
negative patients, which causes serious distortions of the data upon which the 
sensitivity and specificity are based.''6 It has been suggested that ROC curves and 
their AUC are rather insensitive to verification bias.4·7 
The aim of the present paper is to present and illustrate the derived equations 
with empirical data of two potential diagnostic tests. Furthermore, we aim to 
investigate how sensitive ROC curves and AUCs are to verification bias. 
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Methods and empirical data 
Methods 
Two data sets of diagnostic test results are available. First it is shown that the data 
of patients with as well as without the disease fitted logistic and normal 
distributions, respectively. Monotonous transformations are applied and extremely 
influential observations will be deleted. Such monotonous transformations do not 
have any effect on the estimation of the ROC curve.' The Kolmogorov-Smirnov 
test is used to test whether the empirical distributions fitted the theoretical 
distributions.' 
Next, ROC curves are constructed by using as many cut-off points as possible 
and AUCs are calculated with the trapezium method, a non-parametric method,10 
and with the Dorfman-Alf method for normally distributed test results.11 
To show that with one pair of a true and a false positive rate at any cut-off 
point the ROC curve and its AUC can be estimated with a simple formula, we 
chose nine different levels of test results as possible discrimination threshold and 
calculated the true and false positive rate at each point. Next, we substitute those 
rates in the suitable equations for the ROC curve and the AUC. 
The equations used for the estimation of the ROC curve and AUC, for 
distributions of patients and non-patients with unequal variances, are presented 
here. The derivations as well as equations for distributions with equal variances 
are presented in Appendices 1 and 2 for logistically and normally distributed test 
results, respectively. 
For test results from two logistic distributions with unequal variances the 
resulting equation for the shape of the ROC curve is: 
{<y^\y • —
л
 ^ — r
1 
x' * (1 - x)' * e-b 
for χ 6(0.1). a A b = ln[ ra/q-гаРд (!) 
od {FPR I (1 - FPRff 
where ab is the standard deviation of test results of the patients without the disease 
and Oi is the standard deviation of test results of the patients with the disease. 
The AUC can be calculated with a numerical method, such as Simpson's rule.12 (2) 
For two normal distributions with unequal variances the estimate for the shape of 
the ROC curve is as follows: 
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<Ь ОІУ - Ф(Ь + о' ф-1*(х))1 for χ e (0,1), b = фідТК) - σ' *\FPK), о' - -^ 
о. 
where Φ = the standard normal distribution function 
Φ'
1
 = the inverse of the standard normal distribution function (3) 
The AUC is estimated as: 
φ [_І ' i] (4) 
Το investigate the influence of verification bias on ROC curves, one 
discrimination threshold is chosen below which a lower fraction of patients is 
"referred for verification" than above it, i.e. differential referral is introduced. 
This comes down to choosing a certain fraction of the patients below the 
discrimination threshold and all patients above the threshold (Appendix 3). The 
probability densities of test results before and after referral are estimated and 
recalculated to 100% for several referral probabilities. Next, ROC curves are 
constructed, using the full probability densities. 
Empirical data 
Preoperative blood samples had been collected from 2SS patients who were going 
to have an operation for either colorectal carcinoma (n=198) or a benign 
colorectal disorder (n=57) between January 1985 and June 1990 in the University 
Hospital in Nijmegen. In the sera, the concentration of serum tumour marker CA 
19-9 was assessed as this might be of diagnostic value for colorectal carcinoma. 
The study dealing with the diagnostic power of CA 19-9 has been described in 
more detail elsewhere.'3 
It was noticed that serum iron concentrations of acute myocardial infarction 
(AMI) patients were lower than that of healthy controls and for that reason serum 
iron could be of diagnostic value for AMI. Therefore, blood samples, taken from 
AMI patients (n=84) and population controls (n=84) in 1986-1987 in the 
Zuiderziekenhuis Hospital in Rotterdam were used to determine the iron 
concentration in the serum. The original case-control study as well as the study 
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into the diagnostic power of serum iron have also been described elsewhere и " 
Results 
The data set of the colorectal disorder patients comprised 198 patients with 
colorectal carcinoma and 57 patients with benign colorectal disorders Of ten 
patients with carcinoma, data on CA 19-9 were missing and they were excluded 
from the analyses The set of patients with myocardial infarction comprised 84 
AMI patients and 84 population controls Of one patient with AMI information on 
serum iron concentration was not available and this patient was also excluded 
Table 1 gives an overview of the observed distributions of CA 19-9 and serum 
iron for patients with and without colorectal carcinoma and acute myocardial 
infarction, respectively Means and standard deviations are shown before and after 
a monotonous transformation 
Table I Distribution of test results in patients with and without colorectal carcinoma 
(CC) and acute myocardial infarction (AMI), respectively 
CA 19-9 (arbitrary Serum iron (ng/ml) 
U/ml) 
Distribution parameters 
Patients Patients Patients Patients 
with CC without CC with AMI without AMI 
N 
Mean 
SD 
Mean of transformed data 
SD of transformed data 
179 
6166 
119 79 
Э 38 
1 16 
57 
26 74 
45 13 
2 78 
1 01 
83 
14 40 
6 0 0 
2 58 
0 4 4 
84 
17 92 
6 0 0 
2 83 
0 34 
Figures la and lb present the distributions of the serum tumour marker CA 19-9, 
separately for patients and controls, after monotonous logarithmic transformations 
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without colorectal carcinoma 
Figure 1 Logistic distribution function and empirical distribution function of serum 
tumour marker CA 19-9for (a) patients with colorectal carcinoma (n—lT9) and 
(b) patients with benign colorectal disorders (n=57), = exact logistic 
distribution function; = empirical distribution function 
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In the data of the patients with colorectal carcinoma the seven highest observations 
were deleted, because they were too extreme and had too much influence on the 
distribution. The Figures also show the shape of the exact logistic distribution. As 
is clearly visible, the two empirical distributions fit the exact logistic one 
reasonably well, the statistic of the Kolmogorov-Smirnov test for the patients being 
0.98, p-value > 0.20, and for the non-patients 0.76, p-value > 0.20. 
Figure 2a and 2b show the monotonously logarithmically transformed 
distributions of serum iron for patients with and without acute myocardial 
infarction separately. The two graphs fit normal distributions reasonably well, the 
statistic of the Kolmogorov-Smirnov test for the patients being 0.76, p-value > 
0.20, and for the non-patients 0.75, p-value > 0.20. 
ROC curves 
Figure 3 displays the ROC curves of CA 19-9 for colorectal carcinoma as 
estimated with equation 1 for logistic distributions with unequal variances and the 
ROC curve as estimated using all possible cut-off points of the entire distributions. 
The curves estimated with the equation from one combination of a true and one 
false positive test result do not differ much from the method using the entire 
distributions of test results. Only at both extreme cut-off points, the estimated 
curves are overestimations of the curve of the entire distribution. 
Figure 4 shows the ROC curves of serum iron for acute myocardial infarction 
as estimated with equation 3 for normal distributions with unequal variances and 
the ROC curve estimated using all possible cut-off points of the entire 
distributions. Again, the curves estimated from one sensitivity and specificity do 
not differ much from the method using both entire distributions. In the lower part 
of the ROC curves they are underestimates, whereas in the upper part they are 
overestimates. The ROC curves of the two lowest cut-off point are overestimations 
of the ROC curve. 
AUCs 
Table 2 presents the investigated cut-off points for test positivity and the AUCs, as 
calculated with Simpson's rule for logistic distributions with unequal variances, 
mentioned above, as well as their standard errors, calculated according to the 
method of Bamber, which is shown to be the maximum standard error.'" The 
calculation of this SE is as follows: 
Transformed serum iron of patients 
with myocardial infarction 
Transformed serum Iron of patients 
without myocardial infarction 
Figure 2 Standard normal distribution function and empirical distribution function of 
serum iron for (a) patients with acute myocardial infarction (n=83) and (b) 
patients without acute myocardial infarction (n=84). = exact standard 
normal distribution function; = empirical distribution function 
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Figure 3 ROC curves of enure distribution of CA 19-9 and as estimated with equation 1 
for logtstically distributed test results. The nonconnected · 's represent the 
ROC-curve using the full distributions. The other curves fit exactly that cut-off 
point used for estimation of the ROC curve, o. For used individual cut-off 
points and their true and false positive rates, see Table 2 
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Figure 4 ROC curves of entire distribution of serum iron and as estimated with equation 
3 for normally distributed test results. The nonconnected · 's represent the 
ROC-curve using the full distributions, o. The other curves fit exactly that cut­
off point used for estimation of the ROC curve. For used individual cut-off 
points and their true and false positive rates, see Table 3 
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Table 2 Cut-off points for tesl-positivity, estimated areas under the ROC curve and 
standard error for the logarithmically transformed logislically distributed test 
results of CA 19-9 for colorectal carcinoma 
Cut-off point 
(Arbitrary U/ml) 
1.61 
1.95 
2.48 
2.63 
2.89 
3.00 
3.26 
3.47 
3.66 
Mean (equation 1) 
Trapezium method 
TPR 
0.957 
0.931 
0.809 
0.787 
0.691 
0.606 
0.548 
0.426 
0.335 
AUC = 
AUC = 
FPR 
0.915 
0.797 
0.695 
0.593 
0.508 
0.407 
0.305 
0.203 
0.119 
0.66 
0.66 
AUC 
0.67 
0.73 
0.62 
0.67 
0.63 
0.63 
0.66 
0.65 
0.68 
SEM = 
SE = 
SE 
(Bamber) 
0.063 
0.059 
0.065 
0.063 
0.064 
0.064 
0.063 
0.064 
0.062 
0.011 
0.039 
AUC * (1 - AUC) 
(N
s
-l) 
where N
s
 is the number of patients in the smallest group. 
The estimates of the AUC are rather stable, varying a little with a mean estimated 
AUC of 0.66. As was more or less the case with the ROC curves, only at an 
extreme cut-off point an AUC of 0.73 was estimated, probably due to the low 
numbers of patients in the cell for patients without cancer with positive test results. 
Thus, the equation for the AUC for logistical 1 у distributed data seems rather 
robust. The trapezium method estimate of the AUC, using the entire distributions, 
is 0.66, SE = 0.039.10 
Table 3 shows the used cut-off points and AUCs for the serum iron as 
SE, 
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estimated with equation 4 for normal distributions with unequal variances. 
Standard errors are again calculated with the method of Bamber. The normal 
distributions assumption seems, just as the logistics distribution assumption, rather 
robust. The distributions of serum iron were not exactly normal in the acute 
myocardial infarction patients, but the estimates of the AUC vary only a little, 
with estimations between 0.62 and 0.71 with a mean of 0.67. The Dorfman-Alf 
estimation of the AUC, using both entire distributions, is 0.67 with SE = 0.041." 
Table 3 Cut-off points for test-positivity, estimated areas under the ROC curve and 
standard error for the logarithmically transformed normally distributed test 
results of serum iron concentration for acute myocardial infarction 
Cut-off point „ „ SE 
•^ TPR FPR AUC „ . (ng/ml) (Bamber) 
2.08 
2.34 
2.58 
2.62 
2.75 
2.85 
2.87 
3.00 
3.17 
0.940 
0.880 
0.795 
0.759 
0.687 
0.542 
0.470 
0.289 
0.157 
0.905 
0.821 
0.619 
0.500 
0.405 
0.310 
0.202 
0.107 
0.036 
0.66 
0.64 
0.67 
0.71 
0.70 
0.65 
0.67 
0.63 
0.62 
0.052 
0.053 
0.052 
0.050 
0.050 
0.053 
0.052 
0.053 
0.054 
Mean (equation 4) AUC = 0.66 SEM = 0.010 
Dorfman-Alf AUC = 0.67 SE = 0.041 
AUC - • [ β ^ Μ * * '10 0357] - 0.3401 »Φ-'Π - 0.1566]] ш о й 
^0.43Í52 + 0.3410» 
where φ = the standard normal distribution function 
Φ'' = the inverse of the standard normal distribution function 
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Verification bias 
Figure 5a shows the empirical logarithmically transformed, rescaled logistic 
densities of CA 19-9 for patients with and without colorectal carcinoma and the 
densities of test results for these patients after 50% of the test-negative patients 
were referred at a discrimination threshold of 0.0. After verification, the 
distributions clearly are no longer logistically distributed. For the purpose of 
clarity, we only show the densities of test results of patients and non-patients at a 
referral probability of 50%. Figure 5b presents the ROC curves of the original 
distributions and of the distributions at verification fractions varying from 10% to 
100%. It is clear that in this case verification bias does not have serious 
consequences for the estimation of the ROC curve, and thus for the AUC. Change 
of the discrimination threshold did not have real effects on the ROC curves either. 
Figure 6a shows the empirical logarithmically transformed, rescaled normal 
densities of serum iron for patients with and without acute myocardial infarction 
and the density of the test results of these patients after 50% of the test-negative 
patients were referred at a discrimination threshold of 0.0. Again, after 
verification the original distributions are distorted. Figure 6b presents the ROC 
curves of the original distributions and of the distributions at verification fractions 
of 10% to 100%. Again, in our data set verification bias does not have serious 
consequences for the estimation of the ROC curve, and thus for the AUC. Change 
of the discrimination threshold did not lead to serious deteriorations of the ROC 
curve either in this dataset. In the next section, we will discuss the magnitude of 
verification bias in a more general sense. 
Discussion 
With a relatively simple equation, the shape of the ROC curve as well as its AUC 
can be estimated from one pair of a false positive and a false negative rate of a 
diagnostic test. The only restriction put forward here is that the underlying 
distributions of test results is either logistic or normal. Even no information on 
what threshold is used is necessary, only sensitivity and specificity at one cut-off 
point have to be known. As a matter of fact, the cut-off point itself is not even 
interesting, since at each cut-off point the estimate of the AUC with the proper 
equation will be comparitive. 
In both our illustrative data sets the equations for the assumption of the 
underlying distributions are rather robust. Although CA 19-9 was not exactly 
logistically distributed neither in cases nor in controls even after a monotonous 
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Transformed CA 1 9 - 9 of patients with 
and without colorectal carcinoma 
Figure 5a Probability densities of CA 19-9 of patients with and without colorectal 
carcinoma before and after referral of 50% of the patients with a transformed 
CA 19-9 of lower than 0. = density before referral, = density 
after referral 
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Figure 5b ROC curves of CA 19-9 after various fractions of verification 
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Transformed aerum iron of patients with 
and without myocardial Infarction 
Figure 6a Probability densities of serum iron of patients with and without acute 
myocardial infarction before and after referral of 50% of the patients with a 
transformed serum iron of lower than 0 = density before referral, 
= density after referral 
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Figure 6b ROC curves of serum iron after various fractions of verification 
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transformation, the resulting estimated AUC was approximately constant. The 
same holds for the transformed approximately normally distributed serum iron. 
We are currently preparing a manuscript in which equations are derived for 
calculation of the AUC and its variance for other kinds od distributions of test 
results, such as uniform, binomial, and exponential distributions. In this paper we 
will also make clear that the resulting AUC differs considerably, depending on the 
equation in which they are filled in. To put it in other words, the underlying 
distributions of the test results have to be known in order to fill in the true and 
false positive rate in in the proper equation and estimate a reliable AUC. 
Diamond showed that the estimation method he proposed,4 which is the same as 
the equation for the ROC curve for two logistic distributions with equal variances 
that we derive in Appendix 1, is completely invariant to selection bias. To put it in 
other words, although at the chosen decision threshold the true and false positive 
fractions differ before and after verification, the estimated AUC does not change. 
Later on he also presented a series of computer simulations to quantify the effects 
of selection bias on, among other things, the AUC as calculated from equation 2 
and again found the AUC to be stable to selection bias.7 Although the equation is 
indeed insensitive to differential referral, this finding does yet not have any 
meaning, since the test results do not belong to logistic distributions after 
differential verification took place. Thus, the estimation method is not valid any 
longer. As we demonstrated empirically, verification bias may in some instances 
have no real effects on the ROC curve and, consequently, the AUC. Nevertheless, 
the magnitude verification bias depends on the mean test results of the patients and 
of the non-patients, on the standard errors of these test results, on the probabilities 
of verification for patients with positive and negative test results, and on the cut-
off point which is chosen. In Figures 7a and 7b we chose other means and 
standard errors for logistically and normally distributed test results, respectively, 
and in this case serious deteriorations of the ROC curve occur. Hence, clearly no 
general statement can be made about the effect of verification bias on ROC curves, 
but we showed that consequences are to occur possibly. 
All the findings on the stability of AUCs for verification or selection bias are 
based on the assumption that this bias solely depends on the test result and is 
entirely independent of the disease status of the patients under investigation. Biases 
depending on disease status will cause serious distortions in whatever diagnostic 
measure used, including ROC curves and their AUCs. It is likely, however, that 
verification will take place based on the test result, as for the doctor it is unknown 
at this stage what the true disease status of the patient is, so referral for 
verification of the diagnosis will mainly be dependent on the test result. 
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Figure 7 ROC curves of originally (a) logistically and (b) normally distributed data after 
various fractions of referral 
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As mentioned before, the AUC is the preferred measure of diagnostic test 
assessment, for its independency of discrimination thresholds. We have shown that 
it is possible to estimate the AUC even if only one sensitivity and specificity is 
given, for logistically and normally distributed test results. Moreover, this AUC 
is, at least in some instances, rather invariant to verification bias. If the underlying 
distributions of the test results are known, it is possible to investigate the effect of 
verification bias on the ROC curve. Therefore, we would like to advocate the 
estimation of AUCs as the preferred measures of diagnostic power in the 
assessment of diagnostic tests. 
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Appendix 1 
Derivation of the estimate for a Receiver Operating Characteristic curve and its area under 
the curve using one combination of a true and false positive rate for logistically distributed 
data 
Formulation of the model 
Suppose the mean of the test results of healthy persons is ц, and the standard deviation is 
<V 
After a monotonous transformation of the test results as follows 
the distribution of the lest results for Ihe healthy persons is given by 
Fh(jt) = e' for χ e R 
I * e' 
and let the distribution of the transformed test results of the diseased persons be given by: 
0,-9 
Fd(i) - — for ζ б К, a > 0, θ > 0 
1 • «--· 
The relationship between true positive rate TPR and false positive rate FPR at cut-off point 
k· 
(0 FPRk - Pr[xh> k] ' l 
1 +ek 
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(li) TPRt = Pr [xd > к] = l-
1 + e" 
From (ι) it is derived' 
1 - FPRt k
 "
 m ( „„ ) 
Substitution of к in (π) results uv 
(FPRf 
FPR' + (1 - FPR¿* * e~ 
Equation of the Receiver Operating Characteristic curve 
<ÖM)|y - ί -) for χ e (0,1), a > 0 
x' * (1 - x)' • «"· 
After choosing one cut-off point with sensitivity = TPR and 1 - specificity = FPR, the 
ROC curve has to pass through the point (TPR, FPR). So: 
θ , ln[ TPR. (\ -TPR) ^ 
( № * * (1 - FPR)Y 
The parameter 'a' for the diseased persons can be estimated by ajat 
Calculation of area under the Receiver Operating Characteristic curve 
Area under ROC curve, expressed ш θ is: 
AUC = / di - Simpson if a * I (unequal variances) 
Jo
 x' * (1 - x)'*e* 
AUC = f' — dx - - ^— if a = 1 (equal variances) 
Jo
 x' * (1 - χ)'.«"* (1 - e-y 
Appendix 2 
Derivation of the estimate for a Receiver Operating Characteristic curve and its area under 
the curve using one combination of a true and false positive rate for normally distributed 
data. 
Formulation of the model 
Healthy persons: test result \ is normally distributed, with parameter Ν(μ,, af) and 
probability density: 
1 
ЛЦ, 
e 
• tf - *? 
2„: 
Patients with the disease: test result \ is normally distributed, with parameter N(/ij, of) 
and probability density: 
- ! _ . , *i 
J2nal 
The relationship between TPR and FPR at cut-off point k: 
Ί - Mi к - μ. μ. - к (i) FPRt =Pr[ik>k]=Pr [-Í ^ > ^ ] •= Φ (-^ ) 
Xj - U..I к - а. и. - к 
(¿О TPRk = Pr[xd>k] -Pr [-І ^ > ^ ] = Φ (-^ ) 
о, о. а. 
From (ι) and (η): 
(Hi) μ, = σ4 Φ ' ( ^ Λ , ) • к μ, = о,, ф - ' ( Ш , ) + * 
where Φ(χ) is the standard normal distribution function: 
Φ« = ƒ' -7= « * * 
J
- v/2^ 
and Φ '(u) is the inverse function of Φ(χ) 
From (ι): 
к = μ„ - as<bl(FPR¿ 
Substitution of к in (и): 
TPRt - Ф(— f ! 5 — 
Equation of the Receiver Operatine Characteristic curve 
'(УД)I У = * — î " : 'M * ε (0,1) 
After choosing a cut-off point with sensitivity = TPR and 1 - specificity = FPR, the ROC 
curve has to pass through the point (TPR, FPR) So: 
u
rf - u * - oJk-\TPR) - okb\FPR) 
Calculation of area under the Receiver Operating Characteristic curve 
Area under ROC curve (AUC) is: 
Pr [ij > z j - Pr [Xj -xk > 0] = 
expressed in μ,,, μ
ά
, а
ъ
 and σ
Λ
. 
( ι ν ) ^ ^ - ^ - ( μ , - μ ^ - ( ^ - ^ ] = φ [ ^ - μ Μ 
Γϊ 2 ГІ 2 /~2 2 
Substitution of (ш) in (ìv) results in the AUC, expressed in TPR, FPR, ffk and ad: 
ф
 о
л
<Ь\ТРК\ - oh*l[FPHÌ 
№ * <Ί 
If σ
Λ
 = σ„, then AUC = 
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Part Two 
Applications 

Item assessment in the development of a diagnostic 
motor performance test for myopathy in children 
Abstract 
Children suspected of having a neuromuscular disease are checked for the location 
of this disease. If neurogenic diseases can be ruled out, a very painful muscular 
biopsy is necessary to discriminate between muscular diseases and diseases of 
other, e.g. psychosocial, origin and to determinate the type of myopathy. We 
conducted an assessment study of newly developed motor performance items for 
the diagnosis of myopathy. Seventeen children who had had muscular biopsy for 
this diagnosis in the recent past were subjected to the fourteen items, based on the 
measurement of static, dynamic and explosive muscle strength and muscle 
endurance. Individual items did not have perfect discriminative power, but the 
results are so encouraging as to call for more elaborated study with combinations 
of the items, so that in the future fewer children will have to undergo unnecessary 
muscular biopsies. 
Neuromuscular diseases are characterized by a disturbed muscular function.1 
According to their location, neuromuscular diseases can be classified as follows: 1. 
spinal muscular atrophy; 2. polyneuropathy; 3. myastheny; 4. myopathy.2 
Patients in whom the diagnosis of neurogenic disease can be excluded, but that 
of myopathy cannot be made on the basis of other diagnostic tests must undergo a 
muscular biopsy to discriminate between myopathic disease and disease with other 
somatic or psychosocial causes, and to determine the type of muscular disease, if 
any is present. 
Because the muscular biopsy constitutes a burden on the child3 and the 
available tests for adults, e.g. exercise ergometer, hand-squeeze test, are too 
difficult for children, there is a need for a simple test to discriminate between 
children with and without myopathy. Thus, children without myopathy might be 
spared a biopsy. 
The aim of the present paper is to describe a pilot study into the diagnostic 
performance of newly developed motor performance items. These items, possibly 
after improvement, replaced by or in combination with new ones, should 
eventually be combined to form a test that measures all aspects of muscle force 
and endurance and anatomic location of the disease satisfactorily. To evaluate the 
items, they were applied to patients who had had muscular biopsy in the recent 
past. 
Patients and methods 
Subjects 
Using the Hospital Information System of the University Hospital in Nijmegen, 
patients were selected who had had muscular biopsy in the recent past to determine 
the presence or absence of myopathy or the type of myopathy. 
In view of the progressive nature of myopathies and the possibility that the 
motor functioning of patients with diseases of other origins had improved over 
time, the maximum interval between biopsy and the present investigation was set 
to 18 months. To ensure homogeneity of the patient group further, only patients 
between the ages of six and 11 years were eligible. Children under six years of 
age show considerable variation in muscular development. Moreover, motivation 
of younger children is difficult. In children over eleven years of age the influence 
of puberty on muscular development is considered too great. After information had 
been sent to the parents of the children, they gave informed consent to 
participation of their child. The investigators (WAvdB, GACvdS) were blinded for 
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the true diagnosis of all patients at the execution of the test 
Motor performance items 
Fourteen simple motor performance items were developed, mainly based on static, 
dynamic and explosive muscle strength and muscle endurance of shoulder/arm and 
hip/leg muscles as listed in Table 1 The items were first investigated for 
feasibility in a population comprising IS primary school children of six, nine and 
11 years old and were adjusted where necessary This investigation also gave the 
investigators the opportunity to get familiar with the execution of the items A 
description of the fourteen items can be found in the Appendix, a detailed 
description including necessary equipment is available upon request 
Table I Distribution of the 14 items over various muscle locations, muscle strength and 
endurance 
Location 
Static 
Muscle strength 
Dynamic Explosive 
Muscle 
endurance 
Shoulder/Arm 
Arm-high 
Finger-toe 
Tambourine 
Hammer 
Arm-high 
Tambourine 
Finger-toe 
Heels 
Hip/Leg 
Stairs 
Sit-stand 
Stand-sit 
Balance 
Balloon 
Circuit 
Frog 
Lie-stand up 
Gower 
Heels 
Circuit 
Statistical analyses 
After pretesting in primary school children, 17 patients with a biopsy performed 
all 14 items. To assess the test-retest reliability of the items, seven of the patients 
performed them twice, with an interval of 12 to 24 days between them. Test-retest 
reliability is expressed by the number of differently classified patients on two 
occasions for data dichotomized at above mentioned cut-off point and by Spearman 
correlation coefficients (n=7). 
Diagnostic power of the individual items was assessed by calculating sensitivity 
(Se) and specificity (Sp)4 at an arbitrarily chosen cut-off point as illustrated in 
Table 2, and by making a Receiver Operating Characteristic (ROC) curve for each 
item. For this latter purpose Se's at every possible cut-off point are plotted versus 
the false positive fractions or 100% minus Sp's.*"7 With the trapezium method, the 
area under the curve (AUC) can be calculated as a measure for the diagnostic 
power. A non-discriminating diagnostic test will have an ROC curve coinciding 
with the diagonal and an AUC of O.S, whereas a perfect test will have an ROC 
curve in the upper left corner of the diagram and an AUC of 1.0.' 
Table 2 Classification of subjects according to lest result and biopsy result 
Test 
result 
Positive 
Negative 
Total 
Biopsy 
Myopathy 
a 
с 
a+c 
result 
No Myopathy 
b 
d 
b+d 
Total 
a+b 
c+d 
a+b+c+d 
Sensitivity (Se) = percentage of persons with positive test results m the diseased persons 
(i e myopathy) — a/(a +c), 
Specificity (Sp) = percentage of persons with negative lest results in the non-diseased persons 
fi. e no myopathy) = d/(b+d); 
Se and Sp can range from 0% to 100%. 
However, since the present study comprised a limited number of patients, 
calculation of the AUC was considered meaningful only in that it provides an 
indication of the diagnostic power of the items and the AUC should not be 
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interpreted too strictly. For the same reason, standard errors of the AUC's were 
not calculated. 
For correlation between items Spearman correlation coefficients were 
calculated. Feasibility was observed by the investigators. 
Results 
Twenty-one patients from the Hospital Information System were eligible; one of 
them refused participation, two patients did not show up at four different 
appointments and one patient could not be motivated, so 17 were left for testing 
and analyses. Of the enrolled patients, nine had myopathic disease and eight did 
not. Gender and age were approximately equally distributed across the disease 
groups. Mean time between biopsy and testing was 11 months. 
Table 3 shows the goodness of the items according to four criteria: diagnostic 
power, test-retest reliability, feasibility and inter-item correlation. Because of the 
small numbers, the two reproducibility measures may result in different 
conclusions and furthermore, AUC's and sensitivity and specificity may not lead to 
the same conclusion about the validity of an item. An example of ROC curves is 
given in Figure 1, which shows ROC curves of the items Lie-stand up. Stand-sit 
and Gower. 
Seven items gave rise to feasibility problems, mainly standardization (Arm-
high, Stand-sit, Tambourine, Hammer, Finger-toe, Balloon) and difficulty of 
measurement because of the very short time needed to execute the items (Lie-stand 
up. Balloon). 
A number of items measuring dynamic muscle strength of hip/leg muscles were 
included in this study and as expected they were highly inter-correlated (p's > 
0.7). 
Although the results are quite inconclusive, from Table 3 it might be read (with 
precaution) that Stairs, Heels, Frog, Gower, and Circuit aie reasonably good 
items. 
Discussion 
The results of the present investigation are quite encouraging. With fairly simple 
physical test items it may be possible to differentiate between children with a 
disease of muscular origin and children with an impairment of other somatic or 
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Figure I ROC curves of the tests Lie-stand up, Stand-sit and Cower 
psychosocial origin. This means that these items might enable the selection of 
children with a stronger indication for biopsy more efficiently than was hitherto 
possible, and thus some children might be spared a painful biopsy. 
The ultimate goal of developing motor performance tests such as the ones we 
developed is to come to a balanced set of items, measuring all aspects of muscle 
strength and endurance in different body locations. The present study did possibly 
not comprise an ideal set of items to cover all muscle power and endurance aspects 
satisfacorily. Although all patients from the catchment area of the University 
Hospital Nijmegen who underwent muscular biopsy within 18 months prior to the 
study were approached, the study comprised too few patients to permit 
investigation of the diagnostic power of combinations of items. Therefore, at this 
point it is not possible yet to recommend which combination of items should be 
used in clinical situations. A study of larger scale is currently prepared to account 
for these problems. 
The assessment of a new motor performance test is preferably carried out in 
that domain of patients which comprises children who are suspected of having 
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myopathy and, therefore, have an indication for muscular biopsy. This implies that 
a prospective study should be done, which we considered premature, mainly 
because nothing was known of the discriminative power of the new items yet and 
the incidence of myopathies is rather low. For the same reasons we considered it 
justifiable to include patients for whom the only goal of the biopsy was the 
determination of the specific type of myopathy. 
The present study suffers from other limitations. First, potential selection of 
severely ill patients with myopathy on the one hand and children having good 
motor functions without myopathy on the other hand, may have been the cause of 
the promising results. However, this is net very likely in the present study, since 
all children had an indication for muscular biopsy and, therefore, had symptoms of 
muscular weakness. Selection of severely ill patients in this study is rather 
unlikely, since the span of time between the biopsy and the present study was 
carefully chosen, so that the performance of the myopathy patients was not likely 
to have deteriorated. Furthermore, the motor functioning of children without 
myopathy was not likely to have improved significantly in this period. The one 
child who could not perform the test had motivation problems rather than 
problems of severe muscular weakness. 
Second, the diagnostic power of the items was investigated for the age group as 
a whole and possible confounding effects of weight and height could not be con­
sidered because of the low numbers of patients. As said before, a prospective 
study, large enough to obviate all methodological problems, was considered 
premature. Third, inter-rater reliability was not assessed in this study and is 
certainly a feature that should be investigated in future research. 
In conclusion, the present study indicated that it could be possible to develop a 
simple motor performance test for children suspected of having myopathy and, 
thus, it might be possible in the future to spare a great number of them a painful 
biopsy. Further investigation of the presented motor performance items in a larger 
population is recommended. 
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Appendix 
Motor performance items 
In test Stairs the participants have to go up and down an exercise stairway twice. In test 
Arm-high the children have to hold their arms high as long as possible. Test Heels 
measures how far the patients can walk on their heels. In test Frog the participants have to 
jump as far as possible with their feet held together. Test Gower tests the way children 
stand up from a lying position, to determine whether they manifest Gower's manœuvre.' In 
test Finger-toe children have to stand on their fingers and toes, with their hips raised, as 
long as possible. In test Circuit the patients have to walk a maximum of ten rounds at a 
pace which is increased every two rounds. For test Sit-sland children have to get up from a 
chair without support from their hands, whereas in test Stand-sit they have to sit down 
very slowly (in S s) without plumping down. In test Tambourine the children have to strike 
a tambourine alternatively above their heads and agamst their legs in a predetermined 
rhythm. In test Balance the participants have to walk between two converging lines. In test 
Hammer the children have to hit a table with a plastic hammer alternatively on their left 
and right side, respectively, 30 times as fast as possible. In Lie-stand up is the time 
measured which the child needs to stand up. For test Balloon the children have to pick up 
four balloons one by one as fast as possible and to push them through a hole. This test 
should be accomplished without bowing the knees. 
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The tesis Stairs, Arm-high, Tambourine, Hammer, Lie-stand up. Balloon and Finger-toe 
were measured quantitatively on a time scale (seconds), Heels, Balance and Frog were 
measured on a quantitative distance scale (meters), Gower (scores for rum of the body to 
weak side, raising of the hips, and unilateral or bilateral hand support on thighs to 
straighten up), Sit-stand and Stand-sit were measured qualitatively on an ordinal scale 
while Circuit was measured quantitatively on an ordinal scale (number of rounds ш right 
pace) 
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Towards a more standardized assessment 
of diagnostic tumour markers 
Abstract 
Usually, when a new diagnostic tumour marker becomes available some kind of 
assessment, often inadequately, takes place. The estimation of sensitivity and 
specificity are mainly used as summary measures of diagnostic power. 
Unfortunately, the positive assessment outcome is frequently recanted, sometimes 
after years of superfluous use. This may be explained by the fact that only a 
preliminary assessment is done in a highly selected population of already 
diagnosed patients and healthy individuals. Furthermore, diagnostic marker 
outcomes are dichotomised for the calculation of sensitivity and specificity, with 
loss of information as a consequence. We plead for the presentation of all relevant 
diagnostic information, which includes extensive description of the composition of 
the study group, distributions of test results for different patient groups and the use 
of the ROC curve and the area under it as the statistical summary measure. This 
analysis design is developed to prevent future premature introduction of new 
diagnostic tests and will be illustrated by data on CEA for colorectal carcinoma. 
Nowadays, many new diagnostic tests, such as tumour markers, are introduced. 
For evaluation purposes, agreement exists on the assessment of sensitivity and 
specificity of tests,1 but, as was mentioned earlier,2 a standardised, generally 
accepted procedure for recruitment of the population and implementation of the 
studies does not exist, although attempts have been made to introduce such a 
procedure.3 The statistical analyses that are presented are at best overall results, 
without the specification of relevant outcomes. By analogy with the evaluation of 
pharmaceuticals a phased evaluation for diagnostic tests can be formulated. In each 
phase the test must perform well in order to pass to the next phase. 
The first two phases concern an investigation of the ability of the diagnostic test 
to distinguish patients with the target disease from those not suffering from that 
particular disease (i.e. healthy persons, or patients with other diseases). The 
population studied in the first phase may consist of an easily accessible group, 
such as diagnosed patients and healthy individuals. It may be expected that the test 
results of these individuals are at the two extreme ends of the test results 
distribution. Thus, it should be relatively easy to distinguish healthy from diseased 
individuals. On the other hand, many new tests are not able to discern even these 
extreme groups, making their application in clinical practice inappropriate. 
In the second phase study participants should represent the domain population 
of the test. The domain of the test is constituted by the patients that will eventually 
be subjected to the test, i.e. patients who are suspected of having the disease and 
hence form the study population of real interest.4 Compared with phase one, the 
test results of these patients will have moved towards the centre of the distribution, 
rendering it more difficult for the test to discriminate between actual patients with 
and without the target disease. 
In the third phase all other factors relevant to making the diagnosis, such as 
medical history, physical examination, risk factors, complaints, symptoms and 
other diagnostic tests must be considered, in order to assess the place of the new 
test in the current diagnostic arsenal. 
The last phase will be a medical technology assessment in which test order, 
patient burden, costs, benefit, etc., can be studied. 
The present paper will be confined to a more detailed elaboration of the initial 
assessment of a new diagnostic test, illustrated by the classical tumour marker 
carcinoembryonic antigen (CEA) in diagnosing colorectal carcinoma. Since the 
identification of CEA in 19655 the development of new tumour marker tests has 
grown enormously. Although it is generally agreed that CEA is of more value in 
staging colorectal carcinoma than in the primary diagnosis,6-7 it is still primary 
diagnosis it is sometimes recommended for," which could have been avoided with 
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proper assessment procedures. 
Even in the initial stage it is very important to describe the population under 
study extensively so as to improve comparability with other assessment studies. 
The description of a tumour marker may be considered adequate if, for instance, 
the distributions of tumour stage, grade of differentiation and location are shown 
for the patients and the other illnesses are presented for the control group. 
Furthermore, diagnostic test results should be stated separately for the 
abovementioned patient groups. 
Methods 
Preoperative blood samples were taken from 255 patients who had had a curative 
or palliative operation for colorectal carcinoma or an operation for a benign 
colorectal disorder between January 1985 and June 1990. Medical records of all 
patients were investigated to establish the patients' diagnoses. For colorectal 
carcinoma patients, data on tumour location, grade of differentiation and stage of 
disease were collected. Patients were staged according to the modified Dukes' 
classification.' Out of the 255 patients, 198 appeared to have colorectal carcinoma. 
Stage, location and grade of differentiation of the tumours are shown in Tables I, 
2 and 3, respectively. Two patients appeared to have other carcinoma (stomach 
and prostate, respectively), and were excluded from the analyses. The 57 patients 
with benign colorectal diseases showed various forms of pathology, such as 
polyps, diverticular disease, Crohn's disease, etc. (Table 4). 
All blood samples were taken preoperatively by venepuncture. After clotting 
the samples were cemrifuged (10 min at 2000*g) and the sera were stored at -35° 
С until analysis. The serum concentration of CEA was assessed with the "BeriLux 
CEA", an immunoluminometric determination of human CEA (Behringwerke AG, 
Marburg, Germany). 
The results of an assessment study are conveniently displayed by presenting the 
cumulative frequency distribution of patients and controls for marker 
concentrations. Such figures comprise the cumulative frequency of patients as a 
function of the marker concen-tration. Usually, the two distributions for the 
patients with the target disease as well as for the controls (healthy individuals or 
patients from the domain population without the target illness) are graphed in one 
figure. If the cumulative percentage of patients is displayed on the Y-axis, the 
sensitivity and specificity at various cut-off levels can be read directly from the 
figure. The sensitivity of a test is the percentage of patients with a positive test 
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result (percentage true positives), whereas the specificity is the percentage of 
controls with a negative test result (percentage true negatives).10 The distance 
between the two curves gives a rough impression of the diagnostic ability of the 
test; if the two distributions show complete overlap, there is no discriminative 
ability. 
An adequate method of analysing the assessment results is provided by a 
Receiver Operating Characteristic (ROC) curve. An ROC curve plots the 
sensitivity versus 100% minus specificity at various cut-off levels of a test.10·" In 
contrast to the cumulative frequency distribution, one curve suffices to describe the 
discriminative power of a test. The area under the ROC curve (AUC) is the 
measure for the diagnostic ability of the test.12 The ROC curve of a test with no 
discriminative power at all will coincide with the diagonal and its AUC will be 
0.5. A perfect test will have an ROC curve in the upper left corner of the 
diagram. Its AUC will be 1." Computer programs have been developed to 
calculate the AUC of a ROC curve and include the calculation of the standard 
error. This standard error (SE) is used to compute a 95% confidence interval 
(95% CI) (Appendix), without which an adequate description and analysis of the 
evaluation results is incomplete.13,14 
Results 
Tables 1 through 4 present extensive descriptions of the study population and of 
the tumour marker concentration for the different patient groups. The presentation 
of stage of disease (Table 1), location of the carcinoma (Table 2) and grade of 
differentiation (Table 3) for the carcinoma patients and pathology forms for the 
patients with benign disorders (Table 4) make easy comparisons for other 
investigators possible and provide insight in the representativeness of the 
population. 
The cumulative percentage distributions of CEA for cancer patients and benign 
controls are shown in Figure 1. The two distributions are relatively close to each 
other, suggesting little diagnostic power. A nearly 80% overlap of the distribution 
of the cancer patients with that of the controls having benign disorders exists. 
Thus, at 100% specificity (cut-off level 20 ng/ml), CEA shows a sensitivity of 
20%. From Figure 1 can also be read that at the occasionally in literature used 
cut-off point of 2.5 ng/ml the sensitivity is 65% (100 minus 35%, 95% CI 58%-
72%) and the specificity is 68% (95% CI 56%-80%). 
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Table 1 Mean, median, minimum and maximum levels of serum CEA for patients 
(n = 198) with colorectal carcinomas, for the various stages of disease, 
according to Dukes ' classification with Astler-Coller modification 
Dukes' Number Median serum Min. serum Max. serum 
stage (*) C E A ' n g / m l CEA, ng/ml CEA, ng/ml CEA, ng/ml 
Bl 
B2 
CI 
C2 
Unknown 
10 
(5) 
36 
(18) 
47 
(24) 
9 
(5) 
47 
(24) 
47 
(24) 
2 
(1) 
3.2 
(0 6) 
3.5 
(0 8) 
10.1 
(3 5) 
26.0 
(218) 
110.4 
(96 5) 
480 0 
(186 5) 
4.6 
(12) 
2.6 
2.1 
4.3 
2.8 
3.0 
30.0 
4.6 
1.4 
0.6 
0.7 
1.0 
0.7 
1.0 
3.4 
6.9 
27 
160 
200 
4100 
6600 
5.7 
Total 198 
(100) 
139.7 
(49 5) 
3.4 0.6 6600 
Table 2 Mean, median, minimum and maximum levels of serum CEA for patients 
(n = 198) with colorectal carcinomas for various locations 
Location 
Number 
22 
(Π) 
12 
(6) 
10 
(5) 
7 
(4) 
4 
(2) 
4 
58 
(29) 
21 
(Π) 
60 
(30) 
Mean serum 
CEA, ng/ml 
(SE) 
27.5 
(10 8) 
11.8 
(4 4) 
29.7 
(19 2) 
541.5 
(510 1) 
46 
(0 6) 
1027 6 
(1024 1) 
94.1 
(48 5) 
320.1 
(314 0) 
100 2 
(53 4) 
Median 
serum 
СЕЛ, ng/ml 
5.7 
7.3 
7.4 
10.0 
4.8 
4.6 
2.8 
3 3 
3.0 
Mm. Max. 
serum serum 
CEA, CEA, 
ng/ml ng/ml 
Coecum 
Ascending colon 
Hepatic flexure 
Transverse colon 
Splenic flexure 
Descending colon 
Sigmoid 
Recto- sigmoid 
Rectum 
1.2 
1.3 
1.8 
3.0 
1.2 
170 
54 
200 
1.0 3600 
6.0 
410 
0.6 2400 
0.7 6600 
0.6 2500 
Total 198 (100) 
139.7 
(49 5) 
3.4 0.6 6600 
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Table 3 Mean, median, minimum and maximum levels of serum CEA for patients 
(n = 198) with colorectal carcinomas for the various grades of differentiation of 
tumours 
Grade of 
differentiation 
Well 
Well/ 
moderately 
Moderately 
Moderately/ 
poorly 
Poorly 
Unknown 
Total 
Number 
(*) 
23 
(12) 
23 
(12) 
105 
(53) 
20 
(10) 
11 
(6) 
16 
(Í) 
198 
(100) 
Mean serum 
CEA, ng/ml 
(SE) 
16.9 
(13 0) 
14.0 
(5 7) 
144.2 
(613) 
71.5 
(44 6) 
55.8 
(45 2) 
615.6 
(455 9) 
139.7 
(49 5) 
Median 
serum 
CEA, ng/ml 
2.7 
5.5 
3.2 
5.4 
3.7 
6.9 
3.4 
Mm. serum 
CEA, 
ng/ml 
1.2 
0.6 
0.6 
1.0 
1.0 
2.1 
0.6 
Max. 
serum 
CEA, 
ng/ml 
290 
120 
4100 
750 
460 
6600 
6600 
Table 4 Diagnoses of patients with benign colorectal disorders (η =57) 
Diagnosis 
Polyps or polyposis 
Diverticular disease 
Crohn's disease 
Ulcerous colitis 
Other" 
Unknown 
Total 
Number 
(%) 
11 
(20 
12 
(21) 
16 
(2«) 
5 
(7) 
8 
(14) 
5 
57 
(100) 
Mean serum 
CEA, 
ng/ml (SE) 
4.6 
(16) 
3.2 
(10) 
2.2 
(0 3) 
2.0 
(0 8) 
2.2 
(0 6) 
2.3 
(0 6) 
2.9 
(0 4) 
Median 
serum 
CEA, 
ng/ml 
2.4 
2 
2.1 
1.5 
1.3 
2.3 
1.9 
Min. 
serum 
CEA, 
ng/ml 
0.7 
0.7 
0.6 
0.6 
1 
1.2 
0.6 
Max. 
serum 
CEA, 
ng/ml 
18 
11 
5 
4.9 
5 
4.3 
18 
Other diseases comprise fat necrosis; appendicular infiltrate; endometriosis; 
fibrotic lumen stricture; nonspecified inflammation; pancreatic pseudoCyste; 
perianal fistula 
The ROC curve is presented in Figure 2. It is situated approximately halfway 
between the diagonal and the upper left corner. Its AUC is 0.70 (95% CI 0.63-
0.77). 
The high proportion of overlap between the distributions of colorectal cancer 
patients and benign colorectal disorder patients as well as the AUC of the ROC 
curve would have pointed investigators to the conclusion that CEA is not very 
suitable for the primary diagnosis of colorectal cancer. 
From results like the ones in Table 1 it might have been concluded that there 
could be a place for CEA in staging patients with colorectal cancer because of the 
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Figure 2 ROC curve for СЕЛ as a diagnostic test for colorectal carcinoma in a study 
group comprising 198 colorectal carcinoma patients and 57 controls with 
benign colorectal disorders 
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clear correlation between the mean and maximum CEA levels and the stage of 
disease. However, the lack of correlation between median CEA levels and disease 
stage and the ROC curve of the "Dukes' D" patients versus the remaining cancer 
patients would have contradicted this conclusion immediately, since an AUC of 
0.73 (95% CI 0.64-0.82) (Figure 3) is no convincing indication of good 
discriminative power. 
Sanslllvlty, % 
20 30 40 SO M 70 80 M ЮО 
Ю0 minus Specificity, % 
Figure 3 ROC curve for CEA as a staging instrument for colorectal carcinoma in a study 
group comprising 198 colorectal carcinoma patients ('Dukes' D" (n=47 vs. 
remaining cancer patients (n = 151)) 
Discussion 
The results presented in this paper demonstrate a known, but infrequently used 
approach to the presentation and analyses of data from tumour marker assessment 
studies. The ROC curve shows the diagnostic power of the test under evaluation 
independently of the cut-off point for positivity of the CEA test used by the 
clinical investigator. Furthermore, the result can be expressed in one measure of 
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effect, the AUC, unlike the currently used sensitivity and specificity which always 
have to be considered simultaneously and are dependent on the cut-off level as 
well. Finally, ROC curves are a very convenient instrument for the comparison of 
different tests for the same target disease, because they are independent of the 
dimension of the tests under comparison. Thus, the ROC curves of, for instance, 
CEA, expressed in ng/ml, and CA 19-9, expressed in arbitrary units/ml, can be 
graphed in one figure. The one with the higher AUC represents the test with the 
stronger diagnostic power. 
The cumulative frequency distributions show the relationship between numbers 
of patients and controls on the one hand and CEA concentrations on the other. If 
desired, sensitivity and specificity at any particular cut-off level can directly be 
read from the figure. A suitable cut-off level can be chosen for clinical practice if 
the assessment results are encouraging enough. For every serum concentration of 
the tumour marker the cumulative frequency percentage for the controls represents 
the specificity percentage at that point, whereas the cumulative frequency 
percentage for the patients represents (100% minus the sensitivity) at the same 
point. 
Even in the first evaluation phase it is important that the spectrum of patients 
reflects the illness spectrum that is seen in clinical practice in order to avoid large 
biases in the assessment results obtained. If only patients with distant metastasis 
had been included in the study, CEA would certainly have shown an ROC curve 
closer to the upper left corner, with a higher AUC, but this would not represent a 
reliable sample of daily medical practice. By explicitly describing the patients as 
was done in the present study, the likelihood of the presence of biases can be 
verified. 
Many of the assessment studies of tumour markers published in the last decade 
fail to meet these basic requirements. Some of them are summarised in Table 6. In 
most cases patients and controls are poorly described.15"19 Also, cut-off points for 
positivity are not always mentioned.17'19 The sensitivities and specificities described 
invariably lacked precision measures, such as standard errors or 95% confidence 
intervals.I5_31 We calculated 95% CIs for all the fractions of the diffe-rent studies 
and incorporated them in Table 6. Nearly all CIs have a very wide range, due to 
the small numbers of patients and controls in the studies. It will be clear that the 
sensitivities and specificities presented in these studies are not very precise and 
accordingly, justify some scepticism in interpreting the results. 
It is obvious that the present method of analysis with ROC curves and 
cumulative frequency distributions is not restricted to the assessment of tumour 
marker assays, but is easily applicable to all tests of which the results are 
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measured on a continuous or a categorical scale, such as creatinephosphokinase in 
the field of cardiology and erythrocyte sedimentation rate in general practice. 
The present study shows a convenient way of presenting and analysing results 
from an assessment study, different from the methodology currently used. Had this 
design and analysis scheme been used more frequently, then this would have 
helped to recognize the low diagnostic power of the CEA test and others in an 
earlier stage of assessment. 
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Appendix 
Equations for the calculation of 95% confidence intervals 
95% CI of Sensitivity = Sensitivity ± 1 
96
 *P^ 
\no of 
Sensitivity χ (1 - Sensitivity) 
patients with target disease 
95* CI of Specificity - Specificity ± 1 96 к Specificity χ (1 - Specificity) \ no of patients without target disease 
95% CI of AUC - ÁUC ± 1 96 χ SE12 
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Comparison of four serum tumour markers 
in the diagnosis of colorectal carcinoma 
Abstract 
The assessment of the diagnostic power of four serum tumour markers, CEA, CA 
19-9, CA 50 and CA 195 for colorectal carcinoma is described, according to 
recently formulated guidelines. Preoperative serum concentrations of the four 
markers were determined in 198 colorectal cancer patients and 57 patients with a 
benign colorectal disorder. The cumulative frequency distributions of the 
malignant and benign group show strong overlap for all markers, which indicates 
low diagnostic ability. This is confirmed by the Receiver Operating Characteristic 
curves, which have areas under the curve of 0.65 (95% confidence interval (CI) 
0.58-0.73) for CA 19-9, CA 50 and CA 195 and of 0.70 (95% CI 0.63-0.77) for 
CEA. The new tumour markers appear to be of slightly less diagnostic value than 
CEA for the primary diagnosis of colorectal cancer, although the discrepancy is 
not statistically significant. The low diagnostic power of CA 19-9, CA 50 and CA 
195 may be due to a high proportion of colorectal cancer patients having the 
Lewis*"*" phenotype, who cannot synthesise these markers. 
Cancer is the second cause of death in the USA and Europe, and colorectal 
carcinoma is the second most prevalent malignancy in these continents. The 
availability of a tumour marker detectable in serum would be helpful in confirming 
the diagnosis of colorectal carcinoma. Since its discovery,1 the use of 
carcinoembryonic antigen (CEA) as a tumour marker has become widespread. 
Unfortunately, CEA appeared to be neither organ-specific, nor tumour-specific.2 
Therefore, CEA is not very useful in the primary diagnosis of colorectal 
carcinoma, but it has proved to be an effective monitor for the follow-up of these 
cancers.3 
The search for new serum tumour markers has favoured the development of 
monoclonal antibodies, which can be raised and directed against circulating 
rumour-associated antigens (TAA). The carbohydrate antigen 19-9 (CA 19-9) has 
been described as potentially useful in the diagnosis of colorectal carcinoma.4,3 
One year later, the carbohydrate antigen 50 (CA 50) was recognised6 as a 
promising diagnostic marker for cancers of colon and rectum. The monoclonal 
antibodies (MAbs) used in the test kits of CA 19-9 have been shown to react with 
sialylated Lacto N-fucopentose II (sialyl-Le*), a circulating epitope of the Lewis 
blood group antigen.' The MAbs reactive with the TAA CA 50 react with two 
different carbohydrate structures, sialyl-Le" and sialosyl-lactotetraose.8 More 
recently, the TAA 195 (CA 195) was described.' The MAbs recognizing CA 195 
have been shown to react with both Le* and sialyl-Le2 epitopes.10 In case of CA 50 
it was reported that it might be tumour-specific (Holmgren et al., 1984), whereas 
CA 19-9 and CA 195 might be organ-specific.1112 In comparison with CA 19-9, 
CA 195 seems to be less often elevated in benign disease, i.e., it might be more 
specific for malignancies than CA 19-9.'3 
It has been reported that individuals with the Lewis*'"'" phenotype cannot 
synthesise CA 19-9, because they lack the necessary fucosyltransferase 
enzyme.1415 In these individuals, CA 19-9 cannot be used for the detection of 
colorectal cancers. The same applies to CA 50 and CA 195, the production of 
which also depends on the enzyme fucosyltransferase. The lack of 
fucosyltransferase concerns approximately 10% of the general population.16 CA 
50, however, reacts to an epitope also containing sialosyl-lactotetraose, which can 
be produced by all individuals, irrespective of their Lewis phenotype. It might 
therefore be a better marker for cancers of colon and rectum than CA 19-9 and 
CA 195. 
The aim of the present study was to compare the value of CEA, CA 19-9, CA 
50 and CA 195 in the detection of colorectal carcinoma. For this purpose 
preoperative levels of the four serum tumour markers in colorectal cancer patients 
114 Chanter 9 
were compared with marker levels in patients with benign colorectal disorders. To 
complete the overview of the value of the preoperative levels of the markers, we 
also investigated their prognostic significance for recurrence of disease. 
Patients and methods 
Patients 
Between January 1985 and June 1990 preoperative blood samples were collected 
from 257 patients who were going to have a curative or palliative operation for 
colorectal carcinoma or an operation for a benign colorectal disorder. Follow-up 
information on recurrence of disease or death was available until November 1991. 
All diagnosis were histologically confirmed after surgery. For the patients with 
colorectal carcinoma the stage of disease, location and differentiation of the 
tumour were assessed. Tumours were staged according to Dukes' classification 
with Astler-Coller modification.17 The type of disease was assessed for the patients 
with a benign colorectal disorder. Of the 257 patients, 198 had a colorectal 
carcinoma. Stage of disease is shown in Table 1. Distant metastases are referred to 
as stage "Dukes' D". Two patients had a carcinoma of the prostate and the 
stomach, respectively, and were therefore excluded from the analyses. The 57 
patients with a benign colorectal disorder showed various forms of pathology, 
which are summarised in Table 2. 
Laboratory methods 
The blood samples were taken by venapuncture prior to cytoreductive surgery. 
After clotting, the sera were centrifuged for 10 min at 2000xg and the serum 
samples were stored at -35 °C until analysis. The immunoassays used were the 
immunoluminometric assay BeriLux CEA (Behringwerke AG, Marburg, 
Germany), the Tandem-R CA-195 immunoradiometric assay (Hybritech Inc., San 
Diego, CA, USA), the microparticle enzyme immunoassay IMx CA 19-9 (Abbott 
Laboratories, Abbott Park, IL, USA) and the Canag Delfia CA-50 time-resolved 
fluoroimmunoassay (Wallac Oy, Turku, Finland). The performance and 
characteristics of these methods have been described previously."·" 
The precision of the assays was calculated for the means of duplicate 
determinations of several different serum pools in terms of within-assay and 
between-assay coefficients of variation (CV„ and CVb, respectively) as described 
by Rodbard.20 The CV„'s ranged from 2.0% (CA 50) to 5.1% (CEA), whereas the 
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CV„'s ranged between 6.2% (CA 195) and 11.7% (CA 50). 
Table 1 Median and maximum leveb of CEA, CA 19-9, CA 50 and CA 195 for patients 
(n=198)* with colorectal carcinomas, for various stages of disease, according 
to Dukes' classification with Astler-Coller modification 
Dukes' 
stage 
A 
Bl 
B2 
CI 
C2 
•D" 
Unknown 
Total 
N 
10 
5 * 
36 
18% 
47 
24% 
9 
5% 
47 
2 4 * 
47 
24% 
2 
1% 
198 
100% 
Median scrum 
CEA, ng/ml 
(max) 
2 6 
(6 9) 
2 1 
(27) 
4 3 
(160) 
2 8 
(200) 
3 
(4.100) 
30 
(6,600) 
4 6 
(5 7) 
3 4 
(6,600) 
Median serum 
CA 19-9, 
U/ml (max) 
18 
(45) 
24 
(84) 
35 
(150) 
30 
(65) 
24 
(1,500) 
73 
(45,000) 
20 
(22) 
30 
(4,5000) 
Median serum 
CA 50, U/ml 
(max) 
11 
(30) 
11 
(75) 
15 
(58) 
11 
(210) 
10 
(410) 
36 
(9,300) 
6 9 
(8 1) 
14 
(9,300) 
Median serum 
CA 195, U/ml 
(max) 
10 
(10) 
10 
(32) 
10 
(55) 
10 
(110) 
10 
(1.100) 
29 
(28.000) 
10 
(5) 
5 
(28,000) 
" Some ofihe individual parameters have missing data 
Table 2 Diagnoses and median and maximum leveh of СЕЛ, CA 19-9. CA 50 and CA 
¡95 for patients with a benign colorectal disorder (n=57) 
Diagnosis 
Polyps or 
polyposis 
Diverticular 
disease 
Crohn's 
disease 
Ulcerous 
colitis 
Other* 
Unknown 
Total 
N 
11 
21% 
12 
21% 
16 
2B% 
5 
7% 
8 
14% 
5 
9% 
57 
100% 
Median scrum 
СЕЛ, ng/ml 
(max) 
2 4 
(18) 
0 7 
(U) 
2 1 
(S) 
15 
(4 9) 
1.3 
(5) 
2.3 
(4 3) 
1 9 
(18) 
Median serum 
CA 19-9. U/ml 
(max) 
24 
(49) 
6 5 
(340) 
16 
(36) 
11 
(39) 
18 
(92) 
27 
(50) 
19 
(340) 
Median serum 
CA 50. U/ml 
(max) 
13 
(25) 
4 4 
(140) 
8 3 
(51) 
5 9 
(18) 
9 6 
(46) 
14 
(17) 
9 5 
(140) 
Median serum 
CA 195, U/ml 
(max) 
10 
(12) 
10 
(58) 
10 
(15) 
10 
(10) 
10 
(20) 
10 
(10) 
10 
(58) 
Other diseases comprise /al necrosis, lipoma, appendicular infiltrate, endometrtoitc colon, 
fibrolic lumen stricture, nonspecified inflammation, pancreatic pseudocysle; perianal fistula 
Statistical methods 
The usefulness of the serum markers for the primary diagnosis of colorectal 
carcinoma was assessed by cumulative frequency distributions and Receiver 
Operating Characteristic (ROC) curves. The cumulative frequency distributions 
display the cumulative percentage of colorectal cancer patients as well as of 
patients with benign colorectal disorders against the serum marker concentration. 
The resulting figures allow the reading of sensitivity and specificity at any 
requested cut-off level for test-positivity. Furthermore, it shows the extent of 
overlap of the marker distribution of carcinoma patients shows overlap with that of 
the patients with benign disorders. ROC curves plot the sensitivity against one 
minus specificity at various cut-off levels of the diagnostic test. A non-
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discriminating test will have an ROC curve which coincides with the diagonal. A 
perfect test will have an ROC curve in the upper left comer of the diagram.21'23 
The area under the curve (AUC), ranging from 0.5 for a non-discriminating test to 
1.0 for a perfect test, is a measure for the diagnostic ability of a test.24 
The usefulness of combinations of markers was assessed by ROC curves as 
well. Combinations of the markers were made by adding and multiplying, 
respectively, the concentrations of markers for individual patients. 
The prognostic value of the markers with respect to first recurrence of disease 
was assessed by fitting a Cox' proportional hazards model for each marker, with 
time from surgery to first recurrence of disease in months as the dependent 
variable.23 Tumour-free status at the end of the study and death were considered 
censored. 
Results 
Table 1 shows the median and maximum serum concentrations of the four 
individual tumour markers for carcinoma patients for the different stages of 
disease. Means are not presented, due to the skew distributions of the four 
markers. To improve the clarity of the Tables, minimum levels of marker 
concentration are not displayed either. These minima approximate the lowest 
detectable concentration for all disease stages, locations and grades of 
differentiation and no increasing trend could be observed in the minima. Maximum 
concentrations of CEA, CA 19-9, CA 50 and CA 195 increase with increasing 
extent of disease. In the case of median levels this trend cannot be observed; they 
are approximately similar in all stages of disease, except for "Dukes' D" (Table 
1). The various tumour locations comprised coecum, ascending coecum, hepatic 
flexure, transverse colon, Henal ic flexure, descending colon, sigmoid, recto-
sigmoid and rectum. The tumour location does not show any relationship with the 
marker concentrations. None of the markers show clear relations with the grade of 
differentiation of the tumours. It is observed that the highest level of the marker 
occurs in tumours of which the grade of differentiation is unknown, but this can 
probably be explained by the stage of disease of these tumours, which were all 
"Dukes' D \ Apparently, in clinical practice the grade of differentiation is 
frequently not established in patients with distant metastases. Table 2 presents 
medium and maximum observed concentrations of the markers in patients with 
benign colorectal disorders. It is noted that the maximum concentration for all 
markers is found in patients with diverticular disease. 
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Figures 1 through 4 display the cumulative frequency distributions for the 
markers. They present a rather similar picture; the distribution of the carcinoma 
patients shows an 80-90% overlap with that of the benign colorectal disorder 
patients, but for all markers a cut-off point can be determined above which 
patients almost certainly have carcinomas. This point is indicated in each figure 
and varies from 18 ng/ml for CEA to 340 arbitrary U/ml, 140 arbitrary U/ml and 
58 U/ml for CA 19-9, CA 50, and CA 195, respectively. 
Figure 5 presents the ROC curves and the corresponding AUC's for the four 
tumour markers. The ROC curves of the newer markers all have an AUC of 0.65, 
with a 95% confidence interval (95% CI) of 0.58-0.73, which is rather low and, 
moreover, even lower than that of CEA (AUC 0.70, 95% CI 0.63-0.77), although 
the difference is very small and not statistically significant. Various combinations 
of the serum tumour markers did not result in a better discriminative ability 
(Figure 6). 
Figure 7 shows tumour-free survival functions for two categories of CA 50 
(CA 50 < 13 U/ml/CA 50 > 13 U/ml), adjusted for stage of disease (two 
categories; Dukes' A, BI, B2/Dukes' Cl, C2, D). Due to the low number of 
recurrences (16), division into more categories led to empty cells. The other 
markers showed very similar pictures and are therefore not shown. In a Cox' 
proportional hazards model marker concentration was held continuous to 
investigate whether a monotonous relationship with the risk of recurrence exists, 
but this could not be found at all, adjustment for age (continuous) and stage of 
disease (two categories; Dukes' A, BI, B2/Dukes' Cl, C2, D) did not reveal any 
association either (p=0.5-0.9). 
Discussion 
Although earlier investigations indicated very promising results for the serum 
tumour markers CA 19-9, CA 50 and CA 195, these markers showed 
disappointingly low diagnostic power in the present study. The very low median 
concentrations alone, presented in Tables I and II point to the poor discriminative 
ability of all markers tested. The ROC curves are in accordance with this finding. 
The three newer markers all have an almost identical ROC curve with an AUC of 
0.65 (95% CI 0.58-0.73). The ROC curve of CEA was even slightly better, 
having an AUC of 0.70 (95% CI 0.63-0.77), which, however, is not statistically 
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Figure 2 Cumulative frequency distribution of colorectal cancer patients (198) and 
patients with a benign colorectal disorder (57) for CA 19-9 
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Figure 3 Cumulative frequency distribution of colorectal cancer patients (198) and 
patients with a benign colorectal disorder (57) for CA 50 
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Figure 4 Cumulative frequency distribution of colorectal cancer patients (198) and 
patients with a benign colorectal disorder (57) for CA 195 
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Figure 5 Receiver Operating Characteristic curves of СЕЛ, CA 19-9, CA 50 and CA 195 
for colorectal cancer patients (198) and patients a with benign colorectal 
disorder (57). AUC=Area under the curve. CEA: AUC=0.70, 95% CI 0.63-
0.77; CA 19-9: AUC=0.65, 95% CI 0.58-0.73; CA 50: AUC=0.65, 95% CI 
0.58-0.73; CA 195: AUC=0.65, 95% CI 0.58-0.73 
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Figure 6 Receiver Operating Characteristic curves for sum and product of CEA, CA 19-
9, CA 50 and CA 195 for colorectal cancer patients (198) and patients with a 
benign colorectal disorder (57) 
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Figure 7 Tumour-free survival of colorectal cancer patients (198) in months according to 
CA 50-concentration and stage of disease. Low CA 50: CA 50 S 13 U/ml; 
High CA 50: CA 50 > 13 U/ml; Low stage: Dukes' A, Bl or B2; High stage: 
Dukes1 Cl, C2or "D" 
significant. Organ-specificity was not investigated in the present study, but the 
tumour-specificity is disappointing. Even CA SO, which has been reported to be 
tumour-specific (Holmgren et al., 1984) does not show a better discriminative 
ability than CEA, which is known to be increased in nonmalignant disorders and 
healthy smokers.36 However, in the study of Holmgren et al.27 58% of the 
carcinoma patient group had disseminated metastases. Furthermore, 19% of the 
control group were patients with pneumonia and 68% were even healthy blood 
donors. The use of these groups, with serum marker concentration on both 
extreme ends of the marker distribution, probably masked the fact that patients 
with early stages of malignant disease have CA SO concentrations comparable with 
those of patients with benign colorectal disorders. 
To investigate the similarity in the performance of the markers further, Pearson 
correlation coefficients were calculated for all markers as presented in Table 3. 
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Table 3 Pearson's correlation coefficients (ρ value) for CEA, CA 19-9, CA 50 and CA 
195 
CEA CA 19 9 CA 50 CA 195 
CEA 
CA 19-9 
CA 50 
CA 195 
0 57 
(0 0001) 
1 
0 59 
(0 0001) 
0 93 
(0 0001) 
1 
0 59 
(0 0001) 
0 91 
(0 0001) 
099 
(0 0001) 
CA 19-9, CA 50 and CA 195 appeared to have a correlation of about 0 55-0 60 
with CEA, but, more interestingly, the new markers showed a very high mutual 
correlation with correlation coefficients ranging from 0 91 to 0 99 Accordingly, it 
is not surprising that they showed comparable diagnostic power for colorectal 
carcinoma Probably, these high correlations can in part be explained by the 
reactivity of all three markers with sialyl-Le* However, some reports indicate 
enhanced, ι e more specific assay performance using MAbs that react with both 
the Le* and the sialyl-Le* epitopes as is the case with CA 195 10 This is not 
confirmed by the present study CA 19-9 and CA 50 have been reported to show 
identical diagnostic results,21 although CA 50 reacts with an epitope also 
containing sialosyl-lactotetraose ' These findings are in accordance with our data 
Combinations of the four markers did not improve diagnostic performance 
significantly, as is clear from Figure 6 This was to be expected from the high 
correlation between the markers Apparently, there is still discussion on the 
diagnostic value of combinations of markers Some authors report improved 
diagnostic power for a combination markers, others report approximately equal 
diagnostic power " я 
Probably, the poor diagnostic power of all three new markers can at least partly 
be explained by the lack of the enzyme fucosyltransferase in approximately 10% 
of the population,16 who have a Le"1"" phenotype and hence cannot synthesize CA 
19-9, CA 50 and CA 195 1 4 1 5 Recently it was suggested that the Le"*" phenotype is 
more frequent in patients with urinary bladder (12 2%) and colorectal (23 8%) 
carcinoma 31 However, in this study the Lewis phenotypes were determined on the 
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erythrocytes, and it has been demonstrated that their phenotype can convert from 
Lewis-positive to Lewis-negative.32 Therefore, as far as studies based on Lewis 
phenotype determination are concerned, the hypothesis is yet to be investigated in 
serum, which does not allow conversion32 and on tumour tissue. 
Only CEA has some relationship with the extent of the disease, as can be 
concluded from the higher CEA concentrations in patients with more extensive 
disease. Therefore, unlike CEA, the markers CA 19-9, CA 50 and CA 195 are 
probably neither useful for the primary diagnosis nor for the staging of colorectal 
carcinoma. Although they were developed from colorectal cell lines,4" there are 
indications that some of these markers could play a role in the diagnosis of 
pancreatic cancer.34"36 In the case of CA 19-9 a sensitivity of 89% is reported at a 
specificity level of 95%,M whereas a sensitivity of 81% at a specificity of 89% is 
described for CA 5035 and a sensitivity of 64% at a specificity of 94% for CA 
195.36 
Our data show that none of the tumor markers had prognostic value, that is, 
none of the markers could predict recurrence of disease within 34 months after 
diagnosis (median follow-up, maximum follow-up is 81 months). 
The three new markers were evaluated in accordance with a so-called first 
phase of diagnostic marker assessment as was described recently." In that paper it 
was indicated that the spectrum of participating patients must represent the 
spectrum of patients that is seen in clinical practice. The colorectal cancer patients 
as well as the benign colorectal disease patients in the present paper are a 
representation of the patients presenting to the out-patient Department of General 
Surgery of a university hospital. The promising diagnostic power of the serum 
tumour markers as described in literature probably results from comparisons of 
serum marker concentrations of colorectal cancer patients with those of healthy 
individuals and patients with non-colorectal benign disorders.11,27 
The methods of statistical analysis used in this paper are also put forward in 
those recently proposed guidelines.18 They form a convenient way of expressing 
the diagnostic power of a test, mainly because they are independent of cut-off 
levels for test positivity. Such an analysis shows sensitivities and specificities at all 
possible cut-off points simultaneously. Cumulative frequency distributions show 
the relationship of these test characteristics for the particular serum marker 
concentrations. Finally, ROC curves provide one summary measure of 
performance, i.e. the AUC, rather than two seperate measures, i.e. sensitivity and 
specificity, which have to be considered simultaneously. Furthermore, ROC curves 
provide the possibility of comparing multiple tests of which the results are 
expressed on different scales, such as ng/ml or arbitrary U/ml as is the case in the 
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present paper. 
It can be concluded that CA 19-9, CA 50 and CA 195 do not appear to be very 
useful in the primary diagnosis of colorectal carcinoma. Probably, they are not of 
value in staging the disease and in prognosis either. Investigation into the value of 
the markers in the monitoring of colorectal carcinoma and the diagnosis, staging 
and monitoring of pancreatic carcinoma is necessary and, indeed, in progress. 
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Definitive conclusions on the ultrasound 
diagnosis of hypertrophic pyloric stenosis 
Abstract 
Objective To assess ultrasound (US) as a diagnostic procedure for hypertrophic 
pyloric stenosis (HPS) in patients with no palpable olive-shaped mass. 
Patients Hundred and five children with a clinical suspicion of HPS because of 
their projectile vomiting, but without palpable mass were investigated through Us. 
History features, symptoms and laboratory test results were also incorporated into 
the statistical analysis. For history features, symptoms and laboratory test results 
on the one hand and for history features, symptoms, lab test results and 
sonographic pyloric measures on the other, the best predicting logistic regression 
model was composed. 
Results Although the prediction of HPS improved for the second model, a perfect 
diagnosis cannot be made. However, at 91% specificity of the final model, only 
9% of the patients with negative test results actually prove to have HPS. The 
positive predictive value is then 94% and the negative predictive value 95%. 
Conclusion The results justify the support of ultrasound as the diagnostic 
procedure of choice for infants suspected of having hypertrophic pyloric stenosis. 
Since the first paper on the ultrasound (US) diagnosis of hypertrophic pyloric 
stenosis (HPS) by Teele and Smith in 1977,' this diagnostic modality has been 
introduced rather rapidly into clinical practice. Today, it has entirely replaced 
radiography with barium enema as the contrast medium and is currently proposed 
as the diagnostic procedure of choice.·4 Although every now and then it is claimed 
that a parameter has been found with which a perfect diagnosis can be made, such 
as the pyloric length1 or a more complicated muscle index,6 we will quantitatively 
substantiate that this is not the case. 
Recently, we have presented guidelines for the assessment of new diagnostic 
tests.7 In these guidelines we advocate a prudent assessment approach in several 
phases. The initial challenge of this assessment consists in selecting the adequate 
patient population, while later on also other determinants of the disease and other 
factors influencing the decision whether or not to use a test are dealt with. We 
have explained that diagnostic tests eventually should be assessed in the population 
of patients with a real suspicion of having the disease. In the case of HPS this 
means that patients with a suspicion of having HPS should be studied. Also other 
determinants of the disease are to be included in a proper assessment study, in 
order to investigate whether the new test should have a place in the diagnostic 
arsenal. 
Traditionally, the diagnosis is made clinically when an olive-shaped mass is 
felt in the abdomen. If no mass can be felt, further diagnostic steps have to be 
taken.' About twenty papers studies on the usefulness of ultrasound in the 
diagnosis of HPS have been published, but virtually all of them included all 
patients, even those having a palpable pyloric mass. This may have led to the 
introduction of a bias toward a higher predictive value of a positive sonogram.' 
Furthermore, the studies presented thus far did not investigate the additional value 
of US to the available clinical and laboratory information. 
The aim of the present paper is to determine the value of ultrasound for the 
diagnosis of HPS, while simultaneously taking into account other relevant factors, 
such as duration of complaints, acidity of the blood, etc. Patients with palpable 
masses are expressly excluded from the study population, as for these patients the 
decision to send them to surgery has already been made. 
Patients and methods 
Patients 
In 1990, sonograms made between January 1984 and December 1989 in the 
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University Hospital Nijmegen because of a clinical suspicion of HPS for all IOS 
babies in whom no mass was palpable, were reviewed by one senior radiologist 
(CH-B). Pyloric muscle length and thickness as well as the pyloric muscle 
diameter were measured. Furthermore, all medical records were checked and 
information on all available relevant clinical factors, physical examination, family 
history and results of other diagnostic tests were gathered by one of the authors 
(MTWvdV). 
Methods 
In order to study the diagnostic power of the US pyloric measures (muscle 
diameter, thickness and length) while simultaneously taking clinical features, 
physical examination, family history and results of other diagnostic tests into 
account, a more advanced analytical method than just calculating sensitivity and 
specificity is necessary. Such a method is logistic regression analysis, which 
estimates the probability of disease presence, conditional on all features that 
influence this probability by synthesizing them quantitatively into a composite 
score. 
Although the main advantage of regression models is that they can handle more 
features simultaneously, there is still a limit to the number of features that can be 
used. If the number of features equals the number of patients, it can be shown 
statistically that a perfectly predicting model can be constructed, even if all 
features are individually no better for prediction than tossing up a coin.10 A rule of 
thumb is that one should not try to fit a regression model when there are fewer 
than ten times as many events -or cases of disease- as there are features in the 
study.11 
Because the present study comprised too many features for inclusion in a 
logistic regression model, the first thing to do was to reduce the number of 
features. For this purpose, clinical features, physical examination, family history, 
results of other diagnostic tests and the US pyloric measures were dichotomized 
and their diagnostic performances were first investigated individually by 
calculating their odds ratios. The odds is the probability of a feature being present 
divided by one minus that probability. Odds can be calculated for patients with as 
well as for patients without the disease. The ratio of these two odds is called the 
odds ratio (OR). We considered only features with ORs of 3.00 and higher (risk 
factor) or 0.33 and lower (protecting feature) to be appropriate for use in 
multivariate analysis. 
Then, the best predicting model of history variables and the results of 
laboratory tests was made to see if a reliable HPS diagnosis can be made based 
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solely on clinical information. Finally, sonographically measured pylorus thic-
kness, diameter and length were included in the model. 
With each model, risk estimates of the patients were calculated. The estimated 
risks were categorized into ten subgroups. For each subgroup it was checked how 
many patients really did and did not have HPS. Sensitivity and specificity were 
calculated for each risk category and plotted in a Receiver Operating Characteristic 
(ROC) curve. The more the ROC curve is located in the upper left corner of the 
diagram, the greater the diagnostic power of the logistic regression model. The 
diagnostic power is measured by the area under the ROC curve (AUC), varying 
from 0.5 for a non-discriminating model to 1.0 for a perfectly discriminating 
model.'2 In such analyses it is not the p-value of the variables in the model that is 
most important for the decision whether or not to keep them included, but mostly 
the extent of improvement of the ROC curve. Thus, it is possible that variables 
have statistically non-significant p-values, and yet contribute to the discrimination 
Df the two patient groups as reflected in a higher ROC curve. Figure 1 shows the 
ROC curves of the two optimal models. With the method of Hanley and McNeil it 
was tested whether the differences between AUCs were found coincidentally or 
not." 
Results 
In this population of patients with no palpable masses, 60 (57%) did have HPS and 
45 (43%) did not. Of the babies with other diseases, 6 (5.7%) had dyspepsia, 8 
(7.6%) had reflux oesophagitis, 6 (5.7%) had hypertony, 1 (1%) had an allergy 
for cow milk, 1 (1%) vomited habitually and for 23 (21.9%) no real cause for 
vomiting could be diagnosed. As was expected, various history parameters, 
symptoms, laboratory results and the sonographic parameters pylorus diameter, 
thickness and length differ significantly in presence or mean value between patients 
with and without HPS. However, in this population boys, first-borns and babies of 
mothers with a complicated third trimester of gestation were not more affected 
than the other babies. On the contrary, babies of mothers with complicated 
pregnancies seem to have a lower probability of developing HPS. All sonographic 
pyloric measures were statistically significantly higher in patients with HPS than in 
the other patients (Table 1). 
Neither age at US, nor weight nor length at US nor the duration of vomiting 
were associated with pyloric diameter, thickness or length, contrary to what has 
been suggested previously,4'·""" so adjustment for these parameters in the logistic 
regression analyses was considered unnecessary (Table 2). 
Table 1 Medical history, laboratory test results and sonographic pyloric measures of 
patients with and without hypertrophic pyloric stenosis (HPS) 
HPS Non-HPS p-value 
patients patients for diffe-
(n=60) (n=45) rence 
Mean (standard error) 
Length of gestation (weeks) 
Age (days) 
Birth weight (g) 
Weight at US (g) 
Birth length (cm) 
Length at US (cm) 
Duration of vomiting (days) 
Age at which vomiting started (days) 
pH of capillary blood 
pC02 of capillary blood (kPa) 
HC03" of capillary blood (mmol/1) 
СГ of capillary blood (mmol/1) 
Base excess of capillary blood (mmol/1) 
Pyloric diameter (mm) 
Pyloric thickness (mm) 
Pyloric length (mm) 
39 (0.3) 
39 (2.9) 
3242 (82) 
3688 (82) 
50 (0.5) 
54 (0.7) 
11 (1.9) 
28 (2.2) 
7.41 (0.01) 
5.9(0.15) 
27.5 (0.60) 
100 (1.0) 
3.0 (0.56) 
13.1 (0.40) 
5.3 (0.31) 
18.8 (0.53) 
39 (0.4) 
51 (4.7) 
3181 (123) 
3829 (148) 
50 (0.5) 
54 (0.9) 
12 (2.4) 
41 (4.1) 
7.38 (0.01) 
5.5(0.17) 
23.4 (0.46) 
106 (1.0) 
-1.3 (0.34) 
5.3 (0.60) 
2.6(0.17) 
7.9 (0.92) 
0.94' 
0.05· 
0.67b 
0.43' 
0.87' 
0.86' 
0.62· 
0.02' 
o.oo· 
0.10" 
O.OO*1 
0.00· 
0.00" 
0.00* 
o.oo· 
0.00* 
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Table 1 Continued 
HPS Non-HPS p-value 
patients patients for diffe-
(n=60) (η=45) rence 
Male gender 
First-born 
HPS in history 
HPS in family 
Gestation complications ui 
trimester 
third 
Proportion of (standard 
70% (7) 
30% (6) 
3% (2) 
13% (4) 
10% (4) 
78% (5) 
33% (7) 
2% (2) 
7% (4) 
16% (11) 
error) 
0.35' 
0.74' 
0.73c 
0.29* 
0 69° 
' Student l-lest; * Wilcoxon signed rank lest; ' McNemar test 
Table 2 Pearson correlation coefficients (p-value) between age, length and weight of the 
child at the time of US and duration of vomiting and pyloric diameter, thickness 
and length 
Age at US 
Weight at US 
Length at US 
Duration of vomiting 
Pyloric thickness 
-0 18(0 07) 
-0.04 (0 73) 
-0 01 (0 93) 
-0.09 (0.38) 
Pyloric diameter 
-0.08 (0.43) 
0.11 (0.29) 
0.16(0.32) 
0.04 (0 68) 
Pyloric 
length 
-0.06 (0.54) 
0.08 (0.42) 
0.09 (0.57) 
0.03 (0.73) 
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Table 3 presents the ORs of the individual parameters. The only parameters left 
for consideration in the logistic model because of their odds ratios > 3.00 were an 
age of starting vomiting under five weeks, a positive sign of base excess, a HC03" 
concentration a 28 mmol/l, a base excess á 0.7 mmol/1, a Cl'concentration of 
105 mmol/l, a pyloric muscle length 2: 14 mm, a pyloric muscle diameter ä 10 
mm and a pyloric muscle thickness ä S.S mm were. 
Of the history variables and the symptoms, the age at which the vomiting 
started is a very strong predictor of HPS. Of the laboratory tests, a positive base 
excess and a HC03" concentration è 28 mmol/l are the strongest predictors. The 
AUC of the ROC curve of the best predicting logistic regression model was 0.85 
(standard error (SE) 0.037). However, at a high specificity, which is required 
because surgery on babies without HPS is considered unacceptible, the sensitivity 
is still rather low, which means that half of HPS cases will be missed. This is not 
acceptable either. 
Introduction of the sonographically measured pyloric size parameters of muscle 
length à 14 mm and diameter ¿ 10 mm improved the model enormously. The 
AUC increased to 0.98 (SE 0.013), which is almost perfect. The increase is 
statistically significant (p=0.005) (Figure 1). Introduction of pyloric muscle 
thickness did not improve the prediction any further. Table 4 presents the final 
best predicting logistic regression function. 
The pyloric muscle index, i.e. the weight-adjusted volume of the hollow 
pylorus, as proposed by Carver et al.6 was calculated and incorporated to replace 
the pyloric length and diameter in our final model. However, no improvement of 
diagnostic performance could be gained by the use of this index. On the contrary, 
the AUC decreased from 0.98 to 0.93 (SE 0.025). 
Discussion 
In the present population of children with a clinical suspicion of HPS, but in 
whom no masses are palpable, the prevalence of HPS is 57%, which is somewhat 
higher than the 43-44% reported earlier.'14 
We investigated the diagnostic performance of the individual sonographic 
measures by adding them individually to the logistic model, but it was not possible 
to predict HPS perfectly with any of them, despite promising findings in the past.3 
Probably, the previous positive results were due to the inclusion of patients with 
palpable masses in the study population. Nor could the pyloric muscle index, as 
proposed by Carver et al.6 discriminate HPS patients from the other patients. 
Ultrasound diagnosis of hypertrophic pyloric stenosis 135 
Table 3 Odds ratios (OR) of medical history features, laboratory test results and sono-
graphic pyloric measures of patients with and without hypertrophic pyloric 
stenosis (HPS) 
Feature 
Medical history features 
Age ( á 39 days) 
Birth weight ( a 3255 g) 
Weight at US ( a 3600 g) 
Birth length (not missing) 
Length at US (not missing) 
Age at which vomiting started (< 5 weeks) 
Gender (male) 
Panty (first born boy) 
HPS in history 
HPS m family 
Gestation complications (in third trimester) 
Laboratory test results 
Base excess of capillary blood (Й 0.7 mmol/1) 
Sign of base excess (positive) 
pH of capillary blood ( 2 7.41) 
НСОЭ" of capillary blood ( b 28 mmol/l) 
pC02 of capillary blood (5.9 kPa) 
Cl'of capillary blood ( £ 105 mmol/1) 
Pyloric muscle measures 
Pyloric diameter (Ь 10 mm) 
Pyloric thickness ( ¿ 1 4 mm) 
Pyloric length (& 5.5 mm) 
OR 
2.0 
І.Э 
1.9 
1.4 
1 4 
4.1 
1.5 
0.9 
0.6 
2.2 
0.6 
4.0 
16.4 
2.8 
3 1 4 
2.3 
4.6 
56.0 
31.4 
143.5 
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Figure 1 ROC curves for the two logistic regression models Model 1 · age at which 
vomiting started, sign of base excess, HCOT, AUC=0 85, SE=0 037.Model 2-
age at which vomiting started, sign of base excess, HCOX, pyloric length, 
pyloric diameter, AUC=0 98, SE=0 013 
Table 4 Best predicting logistic regression function with history variables, symptoms, 
laboratory test results and sonographic pyloric measures 
Variable 
Intercept 
Age at which vomiting started ¿ 4 weeks 
Sign of base excess positive 
НСОЭ- & 28 mmol/1 
Pylône length 2 14 mm 
Pylône diameter 2 10 mm 
Parameter 
estimate 
-7.0666 
3 0857 
0 7868 
3 6475 
4 1966 
3.7438 
Standard 
error 
2 0589 
1 3219 
1 1541 
3 1157 
1.1649 
1.2770 
p-val 
000 
0.02 
0 50 
0 24 
0 0 0 
0 0 0 
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Our data show that in this population a diagnosis cannot be made reliably when 
based on the history, presence of symptoms and results of lab tests alone, although 
m age under five weeks for the start of vomiting, a negative sign of the base 
excess and a HC03' concentration a 28 mmol/I are very strong predictors of 
UPS. However, at 100% specificity, with no unacceptable unnecessary surgeries, 
the sensitivity is about 0%, in other words, test characteristics of diagnostic 
models only including clinical information do not suffice for accurate diagnosis. 
Inclusion of sonographic pyloric measures increased the diagnostic ability 
significantly, although unfortunately it did not result in a perfect diagnosis. At a 
:ut-off point of an estimated probability of 0.9, the specificity is 91% and the 
sensitivity is 97%. At this cut-off point the positive predictive value is 94% and 
the negative predictive value is 95%. At a cut-off point of 0.1 the sensitivity is 
80% and the specificity is 98%. Thus, we are not able ω confirm the finding of 
Forman et al.' that US can detect HPS without any false-positive findings. 
Nevertheless, these data show that US measurement of the pylorus is certainly 
worthwhile. 
In conclusion, sonographic determination of pyloric muscle diameter, thickness 
and length do not diagnose HPS perfectly in a population of children withoul 
palpable masses. Nevertheless, diagnosis improves markedly when the pyloric 
measures of length and diameter are added to the available history features, signs 
uid lab test results. The predictive values of both positive and negative findings 
ire high enough to justify the support of ultrasound as the diagnostic procedure oí 
:hoice for infants suspected of having hypertrophic pyloric stenosis. 
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11 Concluding remarks and future research 
Setting diagnoses is a basic process in medicine with the purpose of ascertaining 
the presence of a particular disease as the cause of the complaints, signs and 
symptoms a patient is presenting. The diagnostic process frequently involves the 
use of diagnostic tests, preferably tests with good diagnostic performance, which is 
determined in assessment studies. The aim of the present thesis was to develop a 
procedure for adequate assessment of new diagnostic tests. This has resulted in the 
guidelines as presented and illustrated in the previous Chapters. The accent has 
been laid on the selection of the proper study population, the statistical summary 
measures to be used and the importance of assessing the contribution of the new 
test to the diagnostic arsenal. 
This Chapter presents some considerations concerning design and analysis and 
the contrast making diagnoses versus assessment. Often, applied research raises as 
many questions as it answers. This is true of the present investigation as well. For 
instance with regard to the elaboration of the medical technology assessment 
phase, which was considered beyond its scope. The last part of this Chapter gives 
some indications for future research, including the contrast of making diagnoses 
versus assessment. 
Considerations on design and analysis 
Indicated Population 
The reason for adding another set of guidelines to the existing ones1"6 can be found 
in the definition of the study population. Although the need to investigate the new 
test in a population suspected of having the disease, and thus having a clinical 
indication to use the test, is commonly recognized,1·3·4·6 most authors of guidelines 
elaborate on the selection of, as we defined it, easily accessible populations. 
Furthermore, even for the selection of an indicated population (i.e. indicated for 
the application of the test), the starting-point of most authors is to gather a 
representative sample of the entire disease spectrum. Although an indicated 
population may be conceptually very clear and obviously the only proper study 
population, its selection in practice poses particular problems, as was explained in 
Chapter 4. An indicated population can probably be defined most precisely in 
terms of eligibility criteria based on complaints, signs and symptoms. It has not 
been elaborated yet how stringent these criteria should be, nor are they easy to 
define in general terms. In one of the scarce examples of a study in which it was 
tried to use an indicated population, the study population was, in our opinion, too 
loosely defined as simply comprising all patients for whom their general 
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practitioner wanted to know the test result, without taking into account what the 
disease indication for the test was.7 
A definition of the indicated population in terms of complaints, symptoms and 
signs has implications for the study design of assessment studies. Prospective 
studies require high effort and money input for prolonged periods of time for the 
accmel of the study population. Retrospective studies require adequately registered 
data, but the reason for testing is often not recorded.' The differential diagnosis, 
another potential entrance to the indicated population, is recorded more frequently, 
but might be seriously influenced by selection on the true disease status. Since 
consistent registration of complaints, symptoms and signs will be difficult to 
implement in daily clinical practice, thus far it seems hardly possible to use 
existing data for diagnostic test assessment in indicated populations. 
Continuous information 
As has sufficiently been shown by now, appropriate statistical methods have been 
developed for maintaining the continuity of continuous data in order to prevent 
information deprivation. Accordingly, for assessment purposes, dichotomization is 
undesirable. The existing practice of dichotomizing diagnostic test results is 
inherent to the behaviour of practitioners in that they decide whether the patient 
has the disease or not. However, it is unnecessary to dichotomize continuous 
diagnostic tests, even for making diagnoses. Eventually, a diagnostic function 
should be constructed, with which the probability of disease presence can be 
estimated for individual patients. It is only on the basis of this probability, rather 
than the result of one particular diagnostic test, that a decision about the proper 
treatment should be taken. 
Building logistic regression models 
When composing the diagnostic function, it makes sense to add variables 
(complaints, signs, symptoms, results of tests) in the order in which they become 
available during the diagnostic process. Since the information about complaints, 
symptoms, signs and the medical history is readily available, this data should be 
entered in the logistic model first. Subsequently, the results of other diagnostic test 
can be added to the best predicting model based on these features, while the new 
diagnostic test is added last. The decision whether a feature should be included in 
the model or not, has to be made on the basis of its contribution to the ROC curve 
of the regression model. Whether a contribution is great enough, depends more on 
common sense and clinical relevance than on statistical significance. 
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Overdetermination 
When a regression model, such as a logistic regression model, is fit to data and 
the number of features in the model exceeds the number of patients in the study, 
the model is said to be overdetermined.' For such models it can be shown 
statistically that a perfectly discriminating model can be constructed, even if the 
features are individually no better than tossing up a coin. A rule of thumb is that 
no regression model should be fitted in which the number of events in the model is 
less than ten times the number of features in the study. 
The problem of overdetermination can occur in different circumstances, for 
instance when developing a test which consists of several items as in the case of 
the motor performance test described in Chapter 6. This test, consisting of 14 
items, was developed and assessed in 17 patients. The low number of eligible 
patients was, among other things, due to the low prevalence of myopathy in the 
general population. Furthermore, the result of a diagnostic test can sometimes be 
expressed in several parameters, as was the case with ultrasonography of the 
pylorus for hypertrophic pyloric stenosis (Chapter 10). Not only pyloric muscle 
length, but diameter, thickness and volume could be measured as well. However, 
the problem of overdetermination will be most prominent when assessing the 
contribution of a new diagnostic test to the existing arsenal, as was also illustrated 
in Chapter 10. Originally, 20 diagnostic features were available for introduction 
into the logistic model, but to do so, at least 200 patients with and without HPS 
would have been necessary. 
Diagnostic Index 
For the assessment of a particular diagnostic test, without taking into account the 
other features in the diagnostic process, there exists a quantitative statistical 
summary measure, viz. the area under a Receiver Operating Characteristic (ROC) 
curve (AUC).10 However, this measure is difficult to interpret. The AUC is to be 
interpreted as the probability that, of a randomly chosen pair of one patient with 
the disease and one without, the test will correctly identify which patient is ill and 
which is not. Furthermore, the AUC ranges only between 0.5 and 1.0 whereas, 
intuitively, a diagnostic index varying between 0.0 and 1.0 is felt to be more 
attractive. 
Another approach to a diagnostic index as a summary measure of diagnostic 
performance could be the following. Imagine a diagnostic test that does not 
discriminate between patients with and without the target disease at all. This test 
will estimate the same prevalence of disease in all test result categories, as is 
graphically expressed in Figure 1. A perfectly discriminating test will estimate a 
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Figure 1 Prevalence of disease as estimated by a non-discriminating test 
disease prevalence of 1 in the category of positive test results and a disease 
prevalence of zero in the category of negative test results (see Figure 2). So a non­
discriminating test will estimate a probability of disease presence equalling the 
disease prevalence in the whole population for each individual patient. The 
variance of this probability is zero. A perfectly discriminating test, on the other 
hand, will estimate a disease probability of one for all diseased individuals and 
disease probability zero for all non-diseased individuals. For this, test the variance 
0. 
ο.β· 
o.* J 
0.2-
)¡sease Prevalence 
. 
Negative Poalllve 
Test result 
Figure 2 Prevalence of disease as estimated by a perfectly discriminating test 
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of the probability will be maximum."'13 The purpose of diagnosis is to achieve 
maximum variance. The ratio of observed and maximum variance could serve as 
an index for the appropriateness of the diagnostic test, ranging from zero to one. 
Such summarization in a diagnostic index can also be calculated for the assessment 
of the performance of a diagnostic logistic regression function. 
Future research 
Syndrome and complaint diagnoses 
The investigation described in this thesis has been restricted to anatomically and 
causally defined illnesses to avoid problems with the golden standard. In fact, 
many illnesses are not defined by an anatomic lesion or causal factor, but some are 
defined by the presence of a certain fixed number of disease characteristics from a 
larger list, such as rheumatoid arthritis, or by the complaint they give rise to, such 
as migraine. Future research should sort out whether the presented guidelines can 
be applied to such illnesses as well and which adaptations, if any, are necessary to 
make the guidelines applicable. 
Absence of a golden standard 
The present investigation has been confined to diseases for which a golden 
standard of determining definitive disease status exists. If this is not the case, as in 
congenital hip dysplasia, for example, methods have to be developed for the 
assessment of new diagnostic tests. Therapy might be interwoven with diagnosis, 
the diagnosis being confirmed when the therapy works. In such cases, it should be 
studied whether randomized clinical trials with therapy and the new test can be 
used for assessment purposes. 
Diseases measured on a continuous scale 
The present thesis was confined to diseases evaluated on a true present/absent 
scale. This implied the use of a logistic regression model for the estimation of the 
prevalence of disease. In situations where disease is measured on a categorical or 
continuous scale, such as CARA or intoxications, it is not the prevalence of 
disease which has to be estimated, but the extent of lung function decrease or the 
extent of intoxication, e.g. in terms of the concentration of the toxic agent in the 
blood. Such outcome measures require statistically suitable models, for example 
linear regression models. Future research should be directed to suitable indices 
used for the quantification of predictive discrimination, such as the multiple 
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correlation coefficient R: u or the concordance probability, or c-index15"17, the 
latter having been developed for evaluating the additional yield of a test to a Cox' 
proportional hazards model. 
Interaction and effect modification 
A topic not addressed thus far concerns the inclusion of interaction terms in the 
logistic regression model. For the purpose of estimating the probability of disease 
presence as well as possible, it might make sense to include interaction terms in 
the regression model, as long as they help move the ROC curve into the upper left 
corner of the diagram. As regards assessing the contribution of a new test to the 
existing set of diagnostic tools, this topic is more complicated and should be 
worked out in future research. 
Medical technology assessment 
In this thesis we have confined ourselves to the assessment of the diagnostic power 
of a test. As a consequence, the final phase of diagnostic test assessment, i.e. the 
medical technology assessment, has only briefly been addressed in the guidelines 
and should be worked out in more detail. Aspects of this phase include cost-
effectiveness, order of testing, patient burden, therapeutic efficacy (did 
management of patient change?), patient outcome efficacy (did morbidity, 
mortality or quality of life improve?) and societal efficacy (benefit-cost analysis for 
society)." 
Assessment versus setting diagnoses 
When the new diagnostic test has been assessed on its individual merits, its 
additional value to the entire diagnostic process is determined by constructing a so-
called diagnostic function." It is well-known that regression functions perform 
optimally in the population they are derived from. Therefore, it is essential to a 
valid judgement about the appropriateness of the derived function for it to be 
validated in a new population.20 
Diagnostic functions do not only provide insight into the additional value of a 
diagnostic test, but are also an instrument for the estimation of the diagnostic 
probability that is used more and more. For the purpose of making a diagnosis, 
i.e. when the direct interest is in the resulting probability of disease presence, the 
estimated probability must reflect the true probability that the patient has the 
disease. Usually, a scoring system is constructed from the logistic regression 
function.21 This enables practitioners to estimate the disease probability in an easy 
way. For the purpose of assessing the performance of a diagnostic function, the 
Concluding remarks and/Шип restanti 147 
interest is in the function as a diagnostic test, not in the resulting disease 
probability for individual patients. As long as patients with the disease can be 
iiscriminated from patients without the disease, the estimated probability need not 
eflect the true disease probability.22 According to Diamond,22 a function that 
jerfectly discriminates and perfectly estimates true disease probabilities does no) 
ixist. For diagnostic test assessment, a perfectly discriminating function is the 
goal. 
'ndex of additional value 
ГЪе performance of a diagnostic function might be assessed by constructing ал 
ROC curve. In future research, an appropriate index of additional diagnostic value 
should be constructed. The contribution of a new test to the function could for 
;xample be expressed by the change in AUC due to the introduction of the new 
est into the model. A measure expressing relative change will be most suitable, 
aking into account that a new test can theoretically contribute much more 
liagnostic performance to a function with an AUC of 0.60 than to a function with 
m AUC of 0.95.a 
As in the case of the AUC, the contribution of the new test to the existing 
liagnostic arsenal can also be assessed by the change in the diagnostic index due 
о the introduction of the new test into the model. Again, a measure expressing 
'elative change should be constructed. 
Conclusion 
Mthough we have not been able to present a complete recipe for the assessment of 
lew diagnostic tests, we feel confident that the prudent procedure provided is 
ilready worthwhile to implement in diagnostic test assessment. Investigations in 
ndicated populations are difficult to carry out and, like medical technology 
issessments, expensive. Of course, it is possible to start assessment immediately 
ivith such medical technology assessment studies. However, when following the 
prudent approach, it is extremely important that the results in the easily accessible 
Kipulation, sometimes haphazardly good, do not lead to immediate implementation 
)f the new test in clinical practice, but serve as the motivation to set up a study in 
in indicated population. 
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Summary 
Summary 151 
An impressive number of new diagnostic tests have been introduced into medical 
practice over the last two decades. Diagnostic tests are used to gain greater 
certainty as to the patient's diagnosis. In the process of making diagnoses the 
probabilities that certain diseases are present are estimated until for one disease the 
probability is high enough to initiate treatment. According to the theory, diagnoses 
are made by the use of Bayes' theorem; the result of a diagnostic test is used to 
reassess the probability of disease presence (Chapters 1 and 2). Preferably, tests 
with a good diagnostic performance are used. The performance of a diagnostic test 
is determined in an assessment study. 
For assessment of new diagnostic tests, the new test is often applied to a small 
number of diagnosed, sometimes severely ill patients and several healthy controls. 
When a large contrast is found between the test results of the two groups, which 
will often be the case, the test is considered good and will be implemented in 
clinical practice. The carcinoembryonic carcinogen (CEA) is a striking example of 
this kind of assessment practice. Soon after its discovery in 1965, CEA became a 
routinely requested test for colorectal carcinoma, while recently it has become 
generally accepted that it is useless in setting this diagnosis. With proper 
assessment procedures diagnostic tests without sufficient diagnostic power can be 
identified, preventing their introduction into clinical practice. 
Statistical summary measures such as sensitivity and specificity, developed for 
updating the probability of disease presence with new diagnostic information, are 
also used for test assessment. The usefulness of sensitivity and specificity is 
hampered by their dependency on the used cut-off point for test-positivity and their 
susceptibility to selection bias. Furthermore, sensitivity and specificity for 
combinations of signs, symptoms, complaints and several diagnostic tests are 
hardly available and cannot be calculated easily because of the mutual dependency 
of these patient characteristics and diagnostic tests. 
Guidelines are presented for a prudent assessment procedure in three phases 
(Chapter 3). Before a real assessment procedure is started, some elementary 
features of the newly developed test have to be investigated, such as measurement 
errors, repeatability and feasibility. In the initial phase of diagnostic test 
assessment, the challenge consists in the selection of the adequate patient 
population: patients with an indication for the newly developed test, i.e. patients 
suspected of having the disease. The selection of the indicated population is very 
important throughout the entire assessment procedure, but difficult to realize, 
because the necessary data is often not recorded in existing data bases, while 
prospective studies require large time and money investment (Chapter 4). The 
second assessment phase comprises the evaluation of the contribution of the new 
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diagnostic test to the existing diagnostic arsenal of signs, symptoms, comorbidity 
and other diagnostic tests. The final phase of diagnostic test assessment involves a 
complete medical technology assessment. Cost-effectiveness of the use of the new 
test, selection and order of diagnostic tests and patients' utilities should be 
evaluated critically. 
The statistical analyses comprise the presentation of the full information content 
of the test applied to the indicated population and the calculation of an adequate 
summary measure, such as the area under a Receiver Operating Characteristic 
(ROC) curve. Logistic regression analysis is the appropriate technique for 
statistical analysis of the contribution of the new test to the existing diagnostic 
arsenal. The construction and the use of ROC curves are elaborated in Chapter 5. 
With the ROC curve and the calculation of the area under the curve (AUC), it is 
possible to get an impression of the new test at one glance. Some diagnostic tests 
measure disease on a true present/absent scale, such as tests for genetic defects. 
Many tests, however, are inherently measured on an ordinal or continuous scale, 
but dichotomized to a yes/no test for practical use. This deprives the test of its full 
informative content. Nevertheless, for such tests AUCs can be estimated yet with 
the methods developed in Chapter 6. 
The second half of this thesis is concerned with applications of diagnostic test 
assessment, according to the guidelines presented in the previous chapters. A 
clinical evaluation tool was developed that could differentiate functionally between 
children with actual myopathy and those with motor dysfunction of other origin. 
This motor performance test might save some children from having to undergo a 
muscle biopsy (Chapter 7). The initial assessment phase is worked out in detail 
and illustrated with the well-known CEA test for colorectal carcinoma as an 
example (Chapter 8). If, after the discovery of CEA assessment studies had been 
carried out in the indicated population, CEA would have been recognized as a 
useless diagnostic test years earlier. The diagnostic power of three newer tumour 
markers for colorectal carcinoma is assessed in the indicated population. The use 
of the proper population revealed even less diagnostic power of the newer markers 
than of CEA, in contradiction to what is suggested in recent literature (Chapter 9). 
The contribution of ultrasonography to the existing diagnostic arsenal for 
hypertrophic pyloric stenosis is assessed as an example of the second assessment 
phase (Chapter 10). The results show that ultrasonography has a significant role in 
the entire diagnostic arsenal for hypertrophic pyloric stenosis. 
Finally, in Chapter 11 some concluding remarks are made and indications for 
future research are given. These indications mainly concern research on 
assessment of new tests for syndrome diagnoses and diseases that are measured on 
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an ordinal or continuous scale, the absence of a golden standard and an index for 
the additional value of a test to the existing arsenal. 
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De laatste twee decennia zijn vele nieuwe diagnostische tests in de klinische 
praktijk geïntroduceerd. Deze tests worden gebruikt om meer zekerheid te krijgen 
over de aanwezigheid van een bepaalde aandoening bij de patiënt. In het proces 
van diagnostiseren wordt normaal gesproken een differentiaal-diagnose opgesteld, 
d.w.z. een lijst van aandoeningen die het meest waarschijnlijk de klachten van de 
patiënt verklaren. De uitslag van een diagnostische test verandert de 
waarschijnlijkheid dat een bepaalde aandoening aanwezig is. Bij het diagnostiseren 
gaat de arts door met het doen van diagnostische tests totdat de kans op 
aanwezigheid van één bepaalde ziekte hoog genoeg wordt geacht om tot 
behandeling over te gaan. Volgens de huidige theorie wordt voor het berekenen 
van de kansen het theorema van Bayes gebruikt. Bij voorkeur worden tests met 
een goed diagnostisch vermogen gebruikt, i.e. de test die in staat is mensen met en 
zonder de ziekte te onderscheiden. Het diagnostisch vermogen van een test wordt 
bepaald in een evaluatiestudie. Deze theorie omtrent het diagnostiseren en het 
evalueren van de waarde van (nieuwe) diagnostische tests wordt in de 
Hoofdstukken 1 en 2, respectievelijk 3 uitgewerkt. 
Een nieuwe diagnostische test wordt vaak in eerste instantie geëvalueerd bij 
gezonde vrijwilligers (om zgn. normaalwaarden te verkrijgen) en bij een klein 
aantal gediagnostiseerde, soms ernstig zieke patiënten. Indien een groot contrast in 
testuitslagen tussen de beide groepen wordt gevonden, (hetgeen vaak het geval is,) 
wordt geconcludeerd dat de test goed is en voor implementatie in de klinische 
praktijkvoering in aanmerking komt. Een treffend voorbeeld van de gevolgen van 
die procedure is de evaluatie van carcinoembryogeen antigeen (CEA). Na de 
ontdekking van CEA in 1965 werd het al snel een routinematig aangevraagde test 
bij verdenking op colorectal carcinoom. Sinds enige jaren is inmiddels algemeen 
geaccepteerd dat de test onbruikbaar is voor het stellen van deze diagnose. Met 
betere evaluatieprocedures kunnen tests met onvoldoende diagnostisch vermogen 
vroegtijdig worden geïdentificeerd, zodat introductie in de kliniek kan worden 
voorkomen. 
In Hoofdstuk 3 zijn richtlijnen voor een voorzichtige evaluatieprocedure in drie 
fasen gepresenteerd. Enkele elementaire kenmerken van de nieuwe test, zoals 
meetfouten, reproduceerbaarheid en praktische uitvoerbaarheid, dienen tevoren 
bekend te zijn. In de beginfase van de evaluatie bestaat de uitdaging uit het 
selecteren van de adequate patiëntenpopulatie. Zo'n populatie dient te bestaan uit 
patiënten met een indicatie voor de toepassing van de nieuwe test, dat wil zeggen 
patiënten verdacht van de ziekte waarvoor de test is ontwikkeld, van wie nog niet 
bekend is wie wel en niet de aandoening heeft. Als het uitvoeren van deze fase 
veel moeite en/of tijd kost, kan eerst een evaluatieonderzoek bij gediagnostiseerde 
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atienten en gezonde vrijwilligers plaatsvinden. In Hoofdstuk 4 wordt uitgewerkt 
at de selectie van een geïndiceerde populatie zeer belangrijk is in het hele 
valuatieproces, maar moeilijk realiseerbaar in een retrospectieve situatie waarbij 
ïen graag informatie zou willen gebruiken van reeds bekende patiënten. Vaak zijn 
ssentiële gegevens over de indicatie tot uitvoering van de diagnostische test niet 
eregistreerd in de bestaande bestanden. Prospectieve studies waarbij deze 
egevens expliciet in kaart worden gebracht zijn kostbaar en nemen lange tijd in 
eslag om het benodigde aantal patiënten te verzamelen. De tweede evaluatiefase 
ehelst het bepalen van de bijdrage van de nieuwe test aan het bestaande arsenaal 
an diagnostica. De laatste fase omvat een uitgebreide "medical technology 
ssessment". Kosten-effectiviteitsanalyse van het gebruik van de nieuwe test, 
electie en volgorde van diagnostische tests plus patiënt-utiliteiten dienen kritisch te 
/orden bestudeerd. 
Als statistische analyse dient met name in de beginfase een cumulatieve 
requentieverdeling van de testuitslagen te worden gemaakt om de volledige 
riformane van de test, uitgevoerd bij de geïndiceerde populatie, te geven. Tevens 
lient een adequate samenvattende maat te worden berekend, bijvoorbeeld het 
ippervlak onder een Receiver Operating Characteristic (ROC) curve (area under 
lie curve, AUC). Logistische regressie is de geschikte analysemethode voor de 
lijdrage van de nieuwe test aan het bestaande diagnostische arsenaal. 
Samenvattende statistische maten zoals sensitiviteit en specificiteit zijn 
lorspronkelijk ontwikkeld voor het bijstellen van de kans op ziekte met nieuwe 
liagnostische informatie. Zij worden echter ook gebruikt voor de evaluatie van 
¡¡agnostische tests. Omdat deze maten afhankelijk zijn van het gebruikte afkappunt 
oor testpositiviteit en bovendien gevoelig voor selectie-bias, zijn ze minder 
;eschikt voor evaluatiedoeleinden. Bovendien zijn sensitiviteit en specificiteit voor 
ombinaties van patiëntkenmerken als klachten, symptomen en uitslagen van 
erschillende diagnostische tests niet bekend en kunnen ook moeilijk worden 
litgerekend vanwege de onderlinge afhankelijkheid van deze patiëntkenmerken en 
estresultaten. 
In Hoofdstuk S zijn de constructie en het gebruik van ROC-curves uitgewerkt, 
»iet behulp van de ROC-curve en zijn AUC is het mogelijk in één oogopslag een 
ndruk te krijgen van de nieuwe test. Sommige diagnostische tests meten ziekte op 
en echte aanwezig/afwezig-schaal, zoals tests voor genetische afwijkingen. Veel 
ests meten echter eigenlijk op een ordinale of continue schaal en worden in de 
iraktijk gedichotomiseerd tot een ja/nee test. Dit heeft tot gevolg dat niet de 
olledige informatie van de test wordt gebruikt. Desalniettemin kunnen ook voor 
leze tests ROC-curves en AUCs worden berekend met behulp van de statistische 
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methoden die in Hoofdstuk 6 zijn ontwikkeld. 
De tweede hein van deze dissertatie is gewijd aan toepassingen van de evaluatie 
van diagnostische tests volgens de gepresenteerde richtlijnen. In Hoofdstuk 7 is 
een pilot-study beschreven naar een klinisch meetinstrument dat functioneel kan 
differentiëren tussen kinderen met een werkelijke myopathie en kinderen met een 
motorische aandoening met andere oorzaak is ontwikkeld. Deze motoriektest zou 
sommige kinderen een uiterst vervelend spierbiopt kunnen besparen. In Hoofdstuk 
8 is de beginfase van evaluatieonderzoek uitvoerig geïllustreerd aan de hand van 
de bekende CEA-test voor colorectaal carcinoom. Het diagnostisch vermogen van 
drie nieuwere rumormarker-tests voor colorectaal carcinoom is bepaald in de 
geïndiceerde populatie. Het bleek dat deze tests nog minder diagnostisch vermogen 
dan CEA hebben, dit in tegenstelling tot wat gesuggereerd wordt in de literatuur. 
Dit onderzoek is gepresenteerd in Hoofdstuk 9. Als voorbeeld van de tweede 
evaluatiefase, waarbij de bijdrage van een nieuwe test aan het bestaande arsenaal 
wordt bestudeerd, is in Hoofdstuk 10 de bijdrage van de echografie aan de 
bestaande diagnostiek van hypertrofische Pylorusstenose bepaald. Uit de resultaten 
komt duidelijk naar voren dat de echografie een belangrijke bijdrage aan de 
diagnostiek levert. 
Tot slot worden in Hoofdstuk 11 enkele concluderende opmerkingen gemaakt 
en tevens suggesties gegeven voor vervolgonderzoek met betrekking tot de theorie 
van het evalueren. Deze suggesties behelzen onderzoek naar evaluatie van nieuwe 
diagnostische tests niet alleen voor welomschreven ziektebeelden, maar ook voor 
syndroom-diagnoses en ziekten die worden gemeten op een ordinale of een 
continue schaal, zoals CARA, onderzoek naar evaluatiestudies waarbij een gouden 
standaard ontbreekt en het ontwikkelen van een index voor de toegevoegde waarde 
van een nieuwe test aan het bestaande diagnostische arsenaal. 
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